full list rate price target
earn chang report pleas see
tabl page
deep dive examin near
potenti long-term rippl effect
think investor visual novel coronaviru giant boulder
thrown lake creat big initi splash upon entri rippl
seen felt reach far shore time initi focu
investor commun big splash creat near-term effect
import question difficult answer effect rippl
long-term impact healthcar industri
wholeprovid physician patient insur cours med-tech compani
report aim updat model revis
price target lower switch top pick elect
procedur exposur price smoke evacu benefit still rate
overweight upgrad equal weight downgrad underweight
near-term believ market appreci sever like durat
revenu declin one immun elect procedur shift
physician offic visit significantli declin may reduc futur procedur
restart elect non-urg procedur like light-switch particularli
physician patient like worri viral transmiss test still
adequ urgent/emerg done procedur requir limit overnight
done outpatient/asc set may better prospect compani
product diagnos treat manag could see increas
case smaller part portfolio net/net like see signific
declin sale profit moreov recent report rais question
weather effect concern second wave may
despit relief money put signific financi strain hospit
system physician associ also ask relief long-term econom
impact stay-at-hom order uncertain economist expect lower
higher unemploy debat low/long high great recess
show healthcar util elast gener higher med-tech use
other excess use could reduc hospit capital-expenditure med-tech price
could see increment pressur med-tech compani like rethink
suppli chain manufactur footprint focu sustain reduc
busi risk good thing could put upward bia cog
reason cautiou med-tech sector
view build risk med-tech industri there potenti
industri fundament deterior valuat could follow extent
long-term pressur procedur volum med-tech may garnish
premium market may return valuat in-lin market
worri rippl effect may felt longer period last
implic seem price valuat today
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
summari rate price target earn chang report chang shown bold
co
barclay research share price target price shown primari list currenc ep estim shown report currenc
current fiscal year estim barclay research fiscal year estim barclay research
weigh med-tech outperform market thu far
may bring long-term implic med-tech healthcar
stock rate action switch top pick
higher risk sever ill
diagnosi current molecular test landscap
outcom patient
potenti second wave season
immun reinfect role serolog test
time global econom restart outlook
financi disrupt healthcar facil
financi disrupt physician practic
dont forget econom sensit healthcar med-tech
headwind physician offic visit lab volum
compani announc higher demand product
product triag monitor
product could higher sale
weigh med-tech outperform market thu far
sinc peak februari healthcar equip suppli sector declin
outperform broader market owe perceiv safeti well product industri bring
help diagnos manag treat patient februari april healthcar equip
 suppli index rel sector trail broader healthcar index
larg weight pharma less immun challengeslikewis
 index perform sinc index
view individu stock perform fairli justifi med-tech name pressur
greater elect procedur and/or capit equip exposur diversifi name
and/or product could see higher sale due fare better
cover barclay cover valiquett us hc servic mitchel meehan lifesci tool diagnost
may bring long-term implic med-tech healthcar
believ bring mani risk factor med-tech industri believ industri fundament deterior
worri valuat may follow extent longer term pressur procedur volum med-tech
may garnish premium market may return valuat in-lin slight premium market
dont see elect procedur hit one look past rippl effect could felt
longer period last implic seem price valuat present
snapshot see near-term put take uncertainti like longer term implic
uncertaintieswhich like havelong term potenti implicationsnear-term covid headwindsnear-term covid offsets-elect procedurespostpon reduc near-term med-tech product usag low lab draw higher med-tech inventori lower devic cash flows-reduc physician offic visit reduc med-tech sale low lab draw fewer refer procedur -financi pressur hospit physician reducedfutur spend med-tech a/r higher -medtech -larg fix cost structur slowingmanufacturingpl raisecog futur periods-diagnost test -product use triag manag treat patients-devic compani lower costs-do continu circul second wave -will treatment work vaccin becom avail -how quickli diagnost test rampup well surveil effort -when stay-at-hom order work-from-hom order lift look like -when govern hospit system facil start lift restrict elect procedur look like -how quickli individu return hospit ambulatori surgeri center procedur physician offic visit -what longer term global econom impact recess unemploy rate etc -what longer term impact physician practic particularli financi stabil consolid becom group practic hospital-own -what longer term impact hospit healthcar facil particularli financi stabil pressur downstream med-tech lower level hospit capital-expenditure spend greater price pressur -what willb impact insur rate deduct high deduct plan -what impact intern govern spend healthcar program barclay medic suppli devic
sector still hold market premium statusw see potenti valuat risk
med-tech large-cap valuat absolut rel pe
med-tech market cap weight index includ histor stock bcr ew gdt ew adjust exclud
period compani reflect acquisit premium compar data unavail bmet cov cfn
stock rate action switch top pick conm
top pick due pullback switch
sinc peak market high share
russel russel healthcar
attribut cnmd under-perform elect procedur exposur
well challeng finish end year reshuffl salesforc
convey market would like back-end load year
bring headwind elect procedur well potenti
pressur capit equip sale busi believ also bring
signific awar market lead suit smoke evacu product
ad smoke evacu portfolio last year acquisit buffalo
filter buffalo filter portfolio consist legaci buffalo filter visiclear
smoke evacu airseal access manag system plumepen smoke
evacu pencil togeth estim product repres roughli million
sale roughli total sale believ greater awar grow
sustain high-teen higher forese futur market place
today significantli under-penetrated
sage recommend highlight benefit smoke evacu
societi american gastrointestin endoscop surgeon sage issu
recommend regard surgic respons crisi sage
recommend laparoscop procedur use devic filter releas
aerosol particl strongli consid due possibl could
contain viru sage note establish effect seen
howev virus releas laparoscopi carbon
dioxid thu er side safeti would appropri
view buffalo filter well known medic commun lead smoke
evacu product market believ guidelin elev concern
around viru transmiss make smoke evacu system must
oper room may medic liabil issu view
provid tailwind smoke evacu portfolio go forward
moreov buffalo filter airseal accret gross bottom line
note compani us cover ethicon us
us olympu jp cover northgat
privat cover also make smoke evacu product case buffalo filter
oem
moreov mani orthoped surgic procedur expos
outpati procedur perform outpati ambulatori surgeri set
may necessarili level restrict ill
patient treat
still like stori maintain overweight
remov top pick recommend due compani near-
term overal exposur elect procedur overal cautiou stanc
med-tech group longer term view remain unchang believ
compani pipelin meaning product anyth believ healthcar
environ shift toward build towardon
med-tech compani need deliv valu custom real innovationand one
size scale may increasingli matter maintain overweight rate
downgrad underweight equal weight
downgrad underweight equal weight compani
impress recent histori acceler underli sale growth profil believ
current busi mix predomin sale mix unit state sale
make expos slowdown current futur environ
sale product categori
sale geographi
believ orthoped market like challeng environ
time come also concern regard compani abil
integr pend wright transact difficult macroeconom environ
also believ hospit capital-expenditure busi could challeng well growth slow
believ pe like remain depress
 barclay medic suppli devic
also concern cash flow gener compani
recent period increas worri like declin like
occur decreas busi upcom quarter
rel busi mix stock also perform better mani peer sinc
market declin februari thu believ rel valuat present less
compel given market outlook
new price target set appli multipl revis
ep estim syk valuat went low ntm ep
absolut basi discount market financi crisi
height hospit capital-expenditure concern
absolut rel pe histori
organ growthorthoped slow hospit capital-expenditure busi face pe ntm absolut pe ntm absolut pe ntm left axisrel pe ntm right axi barclay medic suppli devic
upgrad avano equal weight
upgrad avano equal weight underweight believ thesi
larg play look ahead expect believ market
acut pain intervent pain franchis pressur due elect
procedur exposur respiratori could potenti see benefit though like
enough off-set pain believ pain busi lead avano miss
financi target balanc year said encourag
appoint new cfo prospect longer term cost restructur believ
cfo michael greiner good addit avano manag team believ
pressur could catalyst major restructur program
believ need avano longer term transform price target
sale product categori
sale geographi
model price target adjust
made numer model price target adjust appear
summari rate price target earn chang report page
main chang model incorpor impact well recent
think industri end market stock reduc ep estim
likewis reduc price target target pe except except
lower expect earn volatil rais estim price target
believ net impact may posit owe
product mix kept price target believ balanc sheet
strength dividend off-set earn pressur lead warrant higher pe
multipl also maintain price target long-term sale forecast
higher adjust lower target ev/sal incorpor higher risk premium
given market volatil
coronavirus second lead caus common coldsecond rhinovirus
coronavirus zoonot mean transmit anim
peopl
coronaviru subfamili consist four generaalphacoronaviru betacoronaviru
gammacoronaviru deltacoronaviru basi phylogenet relationship
genom structur first two infect mammal typic caus
respiratori ill human latter two typic infect bird
accord articl written american societi microbiolog novel
coronaviru updat uncoat viru seven human coronavirus hcov
identifi sars-cov
syndrom
betacoronaviru origin like bat
sars-cov mers-cov consid origin
bat like origin rodent
genom sequenc new coronaviru associ
human respiratori diseas china publish analysi show viru
close relat nucleotid similar group sars-lik
coronavirus previous found bat china
context sar mer on-going
first known sar case believ occur late novemb southern
china spread part world juli end sar
attribut success case detect isol quarantin case trace
so-cal break chain transmiss
sar spread close person-to-person contact also thought respiratori
droplet unit state peopl laboratori evid sar infect
attribut contract travel sar region accord
total peopl world-wide becam sick die
mer first identifi saudi arabia still on-going dromedari camel
believ reservoir host anim sourc human though role rout
transmiss unknown viru pass human-to-human close contact
unprotect care patient healthcar associ care largest outbreak
saudi arabia case unit arab emir republ korea
similar typic symptom mer fever cough short
breath pneumonia common alway present patient mer also
asymptomat mer lethal case-fat rate
cui li shi zl origin evolut pathogen coronavirus microbiol
rhode rodney ph novel coronaviru updat uncoat viru american societi
wu zhao yu et al new coronaviru associ human respiratori diseas china natur
timelin major event
cdc nbc cnn ny time media report barclay
offici inform world organ cluster patient pneumonia-lik ill connect wet market within wuhan china believ start sometim late wuhan case report outsid china -- report thailand old woman tourist spent time wuhan trump ban foreign nation china within two week enter case report us washington state man evacu wuhan initi first death link announc new coronaviru call first death occursin franc -- chines tourist-egypt first case california clear sourc exposur -first case latin america trace man return outsid china princess cruis ship quarantin two-week trip southeast asia yokohama japan church jesu secret church link outbreak south two case death sourc see major north lock town lombardi casein sub-sahara nigeria italian report twocas chines declar health emerg intern place wuhan quarantin order barclay medic suppli devic
timelin major event
cdc nbc cnn ny time media report barclay
us death -presid trump announc addit travel restrict iran warn itali south place residentson lockdown itali lock lombardi region pandemic-presid trump ban travel european countri nation emerg declar trigger stafford act-american colleg surgeon recommend postpon elect surgeon gener adviseshospit follow american colleg surgeon updat guidanc elect surgic procedures-spain partial recommend gather trump extend european travelban trump andcdc launch day slow spread campaign peopl stay ft apart-first shot experiment vaccine-san francisco stay home mandate-germani seal borders-venezuela ecuador peru announc nationwid union announc ban non-essentialincom travel-fr nationwid lockdown-nh england suspend non-urg surgeri least trump sign executiveord refer defens product act medic resourc need respond us agre close border non-essenti three-week nation first state issu state-wid stay-at home order-australia new zealand close border africa announc nationwid lockdown surpass china-new zealand beginsa mandatori order lockdown-fr enter state emerg enforc lockdown began week trump extend social distanc april reopen subway long-dist train case pass million globally-dept labor releas stat show american file unemploy previou week-putin extend nation work home end april barclay medic suppli devic
research paper publish annal intern medicin incub period
applic analys pool confirm case januari
februari outsid hubei provinc china confirm case
identifi exposur symptom onset window analysi show median
incub period estim day similar sar
develop symptom within day infect accord world
organ longest potenti incub period thought day
spread human-to-human transmiss viru spread
commun spread close contact well within feet apart respiratori
droplet person cough sneez thought individu highest
risk spread risk symptomat howev recent data point
suggest individu asymptomat also spread viru reason
govern recommend social distanc stay feet away
individu accord cdc viral rna shed declin resolut
symptom may continu day week
correspond new england journal medicin aerosol surfac stabil
compar show remain
viabl aerosol hour copper hour cardboard hour stainless
steel hour plastic hour
reduc spread govern implement social distanc stay-
at-hom lock-down respect locat unit state presid
trump extend coronaviru guidelin america april approxim
american popul cover individu state stay-at-hom order
patient immun respons known cytokin storm review
titl cytokin storm tisoncik et al microbiolog molecular
biolog review describ cytokin storm system inflammatori respons featur
releas seri cytokin includ tumor necrosi factor tnf interleukin il-
interferon ifn ifn chemokin cytokin induc immun
cell releas free radic caus inflamm caus local tissu structur
heal occur fibrosi result persist organ dysfunct
clinic present rang mild diseas non-specif sign
typic sign fever dri cough fatigu short breath dyspnea
figur illustr symptom among adult coronaviru diseas
hospit unit state base upon data covid-net base data
state period march
symptom among adult age year coronaviru diseas
group yr /total
short breath
symptom collect review admiss histori physic exam note medic record
might determin subject object find addit symptom tabl follow less
commonli report symptom also note adult inform symptom hemoptysis/bloodi
sputum rash conjunct seizur
higher risk sever ill
accord cdc consid high-risk sever ill
includ
age older
live nurs home long-term care facil
peopl chronic lung diseas moder sever asthma
peopl seriou heart condit
peopl immunocompromis includ cancer treatment smoke bone
marrow organ transplant immun defici poorli control hiv aid
prolong use corticosteroid immun weaken medic
peopl age sever obes bodi mass index certain
underli medic condit particularli well control
diabet renal failur liver diseas
figur illustr illustr underli condit among adult
coronaviru diseas hospit unit state base upon data
covid-net base data state period march
underli condit among adult age year coronaviru diseas
group yr /total
obes defin calcul bodi mass index miss intern
classif diseas discharg diagnosi code among patient obes obes defin
sever obes defin
among patient chronic metabol diseas diabet mellitu thyroid dysfunct
two diabet mellitu thyroid dysfunct
restrict women age year
diagnosi current molecular test
virus use rna genet code thu one must use specif diagnost test
season flu viru two categori test commonli use
molecular assay includ rapid molecular assay revers transcript polymeras
chain reaction rt-pcr nucleic acid amplif test
test
viral cultur also use provid time result may take day
sell-vial tissu cultur day tradit tissue-cel viral cultur
infecti diseas societi america recommend use rapid influenza molecular
assay rapid influenza diagnost test detect outpati rt-pcr
molecular assay hospit patient rt-pcr design detect
unit state diagnos use vitro diagnost test
receiv emerg use author
cdc receiv eua februari revers transcript polymeras chain reaction
rt-pcr detect viru viru caus respiratori
specimen test kit avail intern reagent resourc irc
support state local public health laboratori depart defens lab among
number labs/compani develop assay
likewis grant eua see figur
april white hous coronaviru task forc estim
point physician office/urg drive thru set
march abbott receiv eua test id platform
point-of-car system small lightweight boxdescrib compani size
small toaster id isotherm nucleic acid amplif technolog
abbott estim system place unit state includ
physician offic urgent care clinic also ramp product id
instrument deliv system week
test result posit return littl minut neg
minut abbott ramp product deliv test per day equat
million month ultim goal increas capac million test
month june higher beyond
recent day walgreen announc open drive id
test center expect retail healthcar organ may likewis
test approv molecular system
point-of-car base physician
fda link emerg use author medic devic includ vitro diagnost test link
becton dickinson state work bring test market
system immunoassay test result healthcar provid
laboratorian physician offic clinic hospit idn also point-of-car
clia-wav devic could also provid test outcom similar time abbott id
accord john hopkin dashboard april pm et million confirm case
global countries/region far greatest number confirm case unit state
follow spain itali death unit
state
global map
grey denot confirm case
outcom patient
three main trajectori note primer
emerg physician american journal emerg medicin includ
mild diseas upper respiratori symptom
sever pneumonia complic acut respiratori distress syndrom
sever complic includ secondari bacteri
infect acut kidney injuri septic shock ventilator-associ pneumonia cardiac
respiratori failur acut respiratori distress syndrom ard lead
caus
accord recent clinic updat jama case facil rate still uncertain
vari wide region high itali low germani
global mortal rate figur illustr data analys
 hospit intens care unit icu admiss casefat percentag
report case age group februari
group yr
lower bound rang number person hospit admit icu die among total age group
upper bound rang number person hospit admit icu die among total age group
known hospit statu icu admiss statu death
chavez long koyfman et al coronaviru diseas primer emerg physician
american journal emerg medicin
ruan et al clinic predictor mortal due base analysi data patient
sb malani del rio pandem us clinic updat jama publish on-line april
support care recommend prefer acetaminophen fda-approv drug treat
pneumonia present antibiot recommend sinc bacteri infect system corticosteroid
treatment viral pneumonia acut respiratori distress syndrom ard recommend
base studi patient china patient requir oxygen patient requir
intens care respiratori support vis-a-vi ventil
april fda grant eua
us steril equip support
decontamin respir
hillrom leader icu bed
product also elect procedur net
edward largest share
diagnost ard
product use diagnos lung failur
acut respiratori distress syndrom
full featur ventil
philip sell non-invas ventil
target hospit
mani ventil compani also
minim equip ventil
ventil compani typic sell relat dispos other includ
bipap devic use ventil
oxygen therapi may help
difficulti breath
use ventil featur
infus solut
product also elect procedur net
denot coverag barclay research inform compani provid inform purpos invest
recommend barclay research
chen zhou dong et al epidemiolog clinic characterist case novel coronaviru
pneumonia wuhan china descript studi lancet
potenti second wave season
seven human coronavirus hcov identifi hcov-
sars-cov mers-cov
hope would follow season pattern similar influenza
howev neither sars-cov mers-cov demonstr evid season
peak winter case occur spring earli summer case
infect mainli occur earli summer
known whether continu earli summer whether escal
autumn next winter
respons request offic scienc technolog polici ostp
nation academi scienc engin medicin conven stand
committe expert help inform ostp critic scienc polici issu relat
emerg infecti diseas public health threat time ask
consult surviv relat temperatur humid
posit season pandem find share
white hous coronaviru task forc
chad roy tulan univers nation primat research center share
group preliminari result dynam aerosol stabil experi sars-
conduct past sever week infecti diseas aerobiolog
program tulan report surprisingli longer half-lif
influenza viru monkeypox viru mycobacterium tuberculosi
test ambient temperatur humid
outsid china studi look daili case growth rate countri region
found highest rate temper
anoth studi geograph region across countri also found invers
relationship temperatur humid incid
committe note given countri current summer climat
australia iran experienc rapid viru spread decreas case
increas humid temperatur elsewher assum
committe note use note pandem influenza strain
exhibit typic season pattern endemic/epidem strain
influenza pandem past year two start northern hemispher
winter three spring two summer three fall peak
second wave approxim six month emerg viru human
popul regardless initi introduct occur
lau sk woo pc yip cc et al coronaviru coronaviru infect hong kong clin microbiol
nation academi scienc engin medicin rapid expert consult surviv
relat temperatur humid potenti season pandem april
ficetola rubolini climat affect global pattern earli outbreak dynam
islam shabnam erzurumluoglu temperatur humid wind speed associ
previous note fda-approv drug treat
march fda
issu emerg use author eua allow
hydroxychloroquin sulfat chloroquin phosphat product donat strateg
nation stockpil sn distribut use certain hospit patient
hydroxychloroquin approv malaria rheumatoid arthriti lupu
risk/benefit well efficaci drug treat wide
fda approv eua larg base small studi franc marseil
studi controversi lead intern societi antimicrobi chemotherapi
isac publish statement articl publish open-label non-
random trial involv hydroxychloroquin azithromycin french studi
intern journal antimicrobi agent isac note articl
meet societi expect standard especi relat lack better explan
inclus criteria triag patient ensur patient safeti
studi china view inconclus other view
show addit benefit rel standard care
recent studi march report zhan zhang md et al renmin
hospit wuhan univers wuhan china see link articl medrxiv non-
peer review site patient patient random placebo
hydroxychloroquin twice daili day admiss addit standard
treatment consist oxygen therapi unspecifi regimen could includ
antivir antibacteri agent immunoglobulin without corticosteroid
day patient hydroxychloroquin treatment group signific
improv symptom reduc recoveri time cough fever
large-scal clinic trial still need underway
nejm compassion use remdesivir patient sever
april new england journal medicin publish result patient
hospit consid sever case thu compassion use
receiv least one dose remdesivir unit state europ
canada japan
result studi
baselin patient receiv mechan ventil
median follow-up day patient improv
includ patient receiv mechan
ventil extub
total patient discharg patient die mortal
among patient receiv invas ventil among
receiv invas ventil
grein jonathan et al compassion use remdesivir patient sever new england
journal medicin april doi
patient receiv full cours remdesivir receiv day
treatment receiv fewer day treatment investig conclud
clinic improv observ patient howev measur
efficaci requir on-going random placebo-control trial viral load data
collect determin suppress clinic respons author also note
interpret result limit small size cohort rel short
durat follow-up potenti miss data lack inform patient
initi treat lock random control group among limit
sever differ approach evalu treat includ
antivir antibodi cell-bas therapi rna-bas treatment none
formal approv use
 small- mid-cap analyst gena wang publish
report april deep dive antivir drug candid
report provid summari current state overview diseas
progress deep dive select antivir candid includ follow
remdesivir gilead cover carter gould
avigan favipiravir fujifilm jt cover
remdesivir phase readout expect april import market
catalyst provid initi evid antivir activ
remdesivir could show sign efficaci moder patient like less clear
benefit sever patient see low bar approv remdesivir efficaci like
would optim patient reach peak viral load sever import factor could
affect data readout time initi dose standard care allow control
arm adequ power detect clinic benefit
favipiravir show clinic benefit limit vitro efficaci suggest need
valid avigan favipiravir approv influenza japan
china studi show superior clinic benefit select pt favipiravir vs
lopinavir/ritonavir arbidol howev favipiravir show limit effect cell infect
efficaci remain unclear better patient select regimen
optim would need establish favipiravir clinic profil
galidesivir like less clinic activ vs remdesivir galidesivir good
safeti profil healthi volunt vitro data suggest inferior activ vs remdesivir
coronaviru see limit opportun galidesivir
vir antibodi candid may superior clinic profil serv broader
antibodi candid may superior clinic profil like broad coverag long
half-lif conveni rout administr intramuscular and/or subq address
mild/moder asymptomat patient well potenti serv prophylact
treatment futur vaccin becom avail
host confer call manag review scienc april
replay transcript speak scienc confer call wang
review scienc behind vir antibodi program report deep
dive antivir drug candid also provid updat
note vir/gsk deal valid platform acceler develop
excerpt gena report
vir antibodi could superior current antivir therapi bridg
antivir futur vaccin
spike protein structur coronaviru three structur protein associ
coronaviru surfac envelop membran envelop spike protein
membran envelop protein involv viru assembl spike protein facilit
viral entri target cell spike protein contain three segment larg
ectodomain transmembran anchor short intracellular tail ectodomain
consist receptor-bind subunit membrane-fus subunit
electron microscop spike protein appear larg protrus clove-shap trimer
three head trimer stalk give coronaviru appear crown
corona mean crown latin wrapp et al scienc
mechan spike protein-medi viral entri viral entri requir bind
receptor host cell surfac viral attach fuse host viral
membran allow viral genom enter host cell recogn
angiotensin-convert enzym entri receptor enter cell via
endocytosi mediat phosphoinositid employ proteas cleav
mediat membran fusion hoffmann et al cell ou et al
commun process allow viral genom releas
vir antibodi target conserv epitop spike protein neutral
use antibodi discoveri platform start test antibodi multipl
strain coronaviru sar patient includ animal-vers coronaviru
pandem start identifi multipl fulli human antibodi
target neutral
although vir antibodi clinic develop would month behind current
antivir therapi vir antibodi wave drug candid could
life im/sq rout administr could provid vir antibodi candid better clinic
profil vs current antivir candid potenti serv prophylact treatment
broad applic vaccin least month
current statu antibodi develop plan move develop
candid clinic jun-aug time frame
peer review studi
immun reinfect role serolog test
interest serolog test
countri region affect reach peak
focu start shift consid think return-to-work model
context serolog test come focu
serolog test measur whether antibodi present amount
antibodi person blood antibodi may initi present earli thu
serolog test use diagnos may help tool determin
infect past develop immun
igm first antibodi made bodi found mainli blood lymph
fluid typic produc rapidli infect igm typic temporari
disappear usual week product igg abundantli found
antibodi bodi found lymph blood intestin last
studi includ confirm probabl case china
median durat igm detect day interquartil rang igg
detect median day interquartil rang symptom
interest recent albeit peer review studi rais question
april pre-print peer review publish medrxiv titl neutral
antibodi respons recov patient cohort
neutral antibodi nab import clear viru import part
immun respons protect treatment viral diseas
studi plasma collect recov patient mild
symptom none patient admit icu median age patient
year rang year patient femal median
length hospit stay day median diseas durat day
investig monitor kinet neutral antibodi nab
develop cours diseas investig found recov
patient gener low titer specif nab patient studi
titer low detect level medium-low
level medium-high high level nab investig found
variat titer nab depend age group elderli patient
like induc higher level younger patient
investig conclud studi titer nab reach peak
day diseas onset remain stabl thereafterwhich
day howev level nab variabl patient fail develop
high titer nab infect
guo li ph et al profil earli humor respons diagnos novel coronaviru diseas clinic
wu fan et al neutral antibodi respons recov patient cohort
new viru long-term data determin long immun last
data sar outbreak show titer igg neutral antibodi peak
month infect subsequ declin least year
accord recent updat publish jama april evid
reinfect evolv current data experi previou virus without
substanti season mutat support hypothesi patient becom
reinfect viru least mani month year initi
march fda issu updat polici diagnost test within
updat polici allow develop certain serolog test market use test
determin test accur reliabl without prior fda review fda
note serolog test less complex molecular test use sole
identifi antibodi viru provid adequ disclosur inform provid
note thing test review fda neg result rule
infect follow-up test molecular test consid
etc fda intend object develop distribut test
march becton dickinson biomedom privat cover announc
releas new point-of-car serolog test detect antibodi blood
confirm past current exposur littl minut test develop
manufactur biomedom biomedom scale manufactur earlier
year provid test china plan ramp manufactur suppli
million test next month test avail
exclus distribut henri schein cover steve valiquett us healthcar
servic accord biomedom sensit test specif
biomedom recommend result use combin
clinic observ test method nucleic acid pcr test
american medic associ may issu specif hcpc code
understand payor like use code pay roughli
april fda grant first still eua serolog test intend
use clinic lab cellex work mayo clinic
april fda note test develop notifi agenc
serolog test avail use
biomedom
coverag barclay research
inform compani
provid inform
purpos
invest recommend
partnership biomedom
bio-rad us cover
privat cover
aytu bioscienc aytu cover
dia sorin dia im cover
biomerica bmra us cover
sb malani del rio pandem us clinic updat jama publish on-line april
multipl vaccin platform develop accord
perspect articl publish new england journal develop vaccin
pandem speed march believ hold greatest potenti
speed market dna- rna-bas platform requir
cultur ferment follow develop recombinant-subunit
accord april candid vaccin clinic evalu
close start anoth candid vaccin preclin evalu
accord milken institut april vaccin develop
vaccin platform statu select vaccin candid exhaust list
candid preclin
candid phase
medium zydu cadila cdh cover
 inovio pharmaceut us
high
 sinovac sva us cover
 codagenix/serum institut india privat
cover
 cansino biolog beij institut
 univers oxford
biotechnolog
 altimmun alt us cover
 vaxart vxrt cover
 greffex privat cover
 univers oxford
phase yet recruit
fast
 sanofi pasteur san fp cover
 clover biopharmaceut privat
cover glaxosmithklin gsk ln
cover papadaki eu
 cover
 univers queensland/gsk/dynavax
us cover
 baylor colleg medicin
 zydu cadilla cdh cover
 institut pasteur themi privat
 tonix pharma tnxp cover
southern research privat cover
 bntx us cover /fosun
 us cover
hk cover cover
carter gould us biopharma
/nation institut allergi
 curevac privat cover
 sanofi san fp /translat us
 medicago inc subsidiari mitsubishi
tanab pharma jp cover
new england journal medicin barclay research
luri nicol et al develop vaccin pandem speed new england journal
cover first vaccin advanc
coverag barclay research inform compani
provid inform purpos invest recommend
januari announc vaccin research center vrc
nation institut allergi infecti diseas niaid collabor compani
design vaccin niaid would conduct phase clinic studi
 term agreement manufactur mrna vaccin
would fund coalit epidem prepared innov cepi
moderna manufactur plan norwood massachusett
five develop candid potenti commerci use use mrna
respiratori syncyti viru rsv vaccin
merck merck us cover carter gould
cytomegaloviru cmv vaccin human metapneumoviru
zika vaccin biomed advanc research develop
three develop candid modal avail potenti global health use
develop defens advanc research project agenc darpa
march first patient dose nih-l phase studi evalu three dose
level administ total adult two-dos
vaccin schedul given day apart patient follow month
second vaccin primari object evalu safeti reactogen
secondari object evalu immunogen sars-
march depart human servic hh announc
collabor prepar phase phase clinic studi
march depart human servic hh also announc
would support non-clin studi phase clinic trial janssen
investig vaccin janssen compani
 js lead vaccin candid vaccin built around
engin version adenoviru vector platform also test
vaccin hiv ebola respiratori syncyti viru zika
 hh plan start phase clinic trial later fall
indic septemb latest start make vaccin februari
barda biomed advanc research develop author support
 hh believ current timelin vaccin avail
emerg use unit state earli begin rapid scale
manufactur capac goal suppli billion vaccin dose
begin product immin risk anticip first batch
vaccin could avail emerg use author eua earli
 significantli expand exist partnership barda togeth barda
 commit billion invest co-fund vaccin
note comment bring afford vaccin public not-for-
profit basi emerg pandem use thu would anticip cost would
charg vaccin would recoup cost develop cost scale
manufactur cost product thu would look vaccin
windfal major posit financi perspect believ right thing
adher compani long-run credo
pleas see two key report written topic sanofi vaccin
larger report pandem review old foe pay us visit san ew
join mrna brigad take mrna vaccin collabor call
sanofi pasteur vaccin global busi unit sanofi two lead vaccin program
first program leverag previou work sar vaccin sanofi use
recombin dna platform produc vaccin candid accord sanofi
recombin technolog procedur exact genet match protein found
surfac viru dna sequenc encod antigen combin
dna baculoviru express platform use rapidli procedur larg
quantiti coronaviru antigen stimul immun system protect
viru sanofi collabor barda program barda
collabor sanofi sinc protein scienc acquir sanofi
sinc vaccin develop work develop protein scienc though
sanofi bring knowledg scale manufactur
second program collabor cover develop
mrna vaccin march compani announc collabor
leverag exist agreement date back agreement
translat begun produc multipl mrna construct mrna
platform discov design manufactur number vaccin candid sanofi
provid expertis support research network advanc candid
potenti develop
coverag barclay research inform compani
provid inform purpos invest recommend
compani also pursuit vaccin
cansino inovio pharma coverag barclay
research inform compani provid inform purpos
invest recommend barclay research
cansino biolog hk cover china-bas biotech compani announc
march advanc recombin novel coronaviru vaccin adenoviru type
vector candid co-develop beij institut
bib enter phase clinic trial april compani announc file
hong kong exchang base preliminari safeti data phase clinic
trial plan initi phase clinic trial china soon vaccin
platform also use develop vaccin ebola accord compani
vaccin replication-defect adenoviru type vector express
spike protein intend use prevent diseas caus novel
vio pharma cover announc april initi phase
clinic trial use candid dna vaccin platform among
first technolog select receiv fund coalit epidem prepared
innov cepi privat cover phase studi enrol healthi
adult philadelphia kansa citi receiv two dose four week apart
initi immun respons safeti data studi expect late summer
accord compani inovio vaccin also studi mer
well toler induc high level antibodi respons subject also
gener broad-bas cell respons nearli studi particip compani
note durabl antibodi respons dna vaccin studi
use maintain week follow dose
other express human trial start soon
bntx cover cover carter gould us pharma
april compani announc addit detail collabor advanc
candid biontech mrna vaccin program origin announc march
collabor aim rapidli advanc multipl vaccin candid
human clinic test two compani plan jointli conduct trial initi us
europ across multipl site initi first clinic trial earli end
cover creat vaccin candid use
proprietari recombin protein nanoparticl technolog platform gener antigen
deriv coronaviru spike protein compani indic initi
phase clinic trial candid may
day lockdown china lift lockdown measur wuhan
first case detect decemb head offici lift resid
govern assign green qr code mobil phone signifi
healthi permit travel abl go back work commun
new case within past day one person per household abl leav two
hour per day even though lockdown lift resid still need show green
germani state lockdown strict quarantin impos across part
countri germani discuss potenti issu immun certif
would allow individu leav lockdown one test posit antibodi unit
kingdom also consid plan antibodi test issu immun passport
franc lockdown april expect anoth
extens follow thereaft due fear lift could lead second wave
infect prime minist talk possibl eas lockdown
measur region-by-region basi subject new test polici itali also
express view return normalci would need achiev gradual
unit state presid trump extend coronaviru guidelin america
social distanc guidelin april approxim american
popul cover individu state stay-at-hom order
consid reopen reopen economi unit state politician debat
balanc act public physic fiscal health variou think tank
weigh topic incorpor view highli regard
figur side polit aisl highlight one whose plan seem
strike us reason approach note former fda commiss author
reopen link
mph epidemiologist assist professor john hopkin center health secur
former deputi director fda medic devic center agenc chief staff
crystal watson drph mph health secur expert assist professor john
hopkin center health secur
what need better data identifi spread rate exposur immun
improv healthcar system capabl includ earli outbreak identif
case contain adequ suppli therapeut prophylact prevent
treatment better-inform medic intervent
phase phase slow spread current phase phase reopen state-by-st
coordin among state share metropolitan region abl
safe diagnos treat isol case contact continu physic distanc
measur limit gather ask peopl wear face mask test
widespread phase establish immun protect lift physic distanc
tool mitig risk avail includ broad surveil therapeut
safe effect vaccin avail phase build readi next pandem
invest expand public-health healthcar infrastructur
view enough test
abl conduct
monitor perform
contact trace like
difficult state achiev
order move phase state would achiev sustain reduct
case least day hospit state safe abl treat patient
requir hospit without resort crisi standard care state abl
test peopl symptom state abl conduct monitor
confirm case contact
tidbit plan relev med-tech compani
plan estim nation capac test capac least test
per week would suffici move case-bas intervent pair
suffici capac support public-health infrastructur contact trace
plan recommend ensur suffici critical-car capac immedi expand
capac critical-car bed bed per adult set
epidem emerg allow region variat plan recommend
maintain access acute-car hospit bed least per adult
plan recommend expand access ventil hospit per
adult goal ventil per adult
phase report state must improv hospital-b icu capac
accommod larg surg patient public-priv partnership
time global econom restart outlook
quickli economi restart close tie lift lift lockdown
stay-at-hom order
relat unit state shown figur unemploy claim
increas past three week greater cumul claim
lehman file bankruptci septemb
view plan longer
term recommend
improv bed icu
hillrom
startingw/ barclay medic suppli devic
april congression budget offic updat econom forecast reflect
pandem reflect effect econom boost recent enact
legisl cbo expect declin would impli
annual growth rate would exceed note declin could much
larger expect unemploy rate exceed would
highest rate seen sinc great recess see figur
look global barclay publish forecast weekli link latest forecast
note arrow appear next number current forecast differ previou week quarterli annual
annual inflat weight use real base imf ppp-base center move averag weight use
consum price base imf nomin center move averag imf ppp-base weight aggreg cpi exclud argentina
last week edit faith polici overcom uncertainti barclay global econom
team includ interest chart includ figur
global economi like experi largest fall sinc wwii likelihood recoveri good certain
financi disrupt healthcar facil
challeng healthcar deliveri system particularli hospit effort
flatten curv put place lower burden system nevertheless
financi stress system hospit gener substanti portion
revenu elect procedur servic oppos emerg
case hospit also incur cost relat pandem prepared capit
suppli well direct care cost patient higher
domino effect ac us surgeon recommend
part initi guidanc cdc issu interim guidanc healthcar
facil prepar commun transmiss unit state
guidelin includ among thing reschedul non-urg outpati visit
reschedul elect surgeri shift elect urgent inpati diagnost surgic
procedur outpati set feasibl
guidelin seem get much attent
march american colleg surgeon issu updat recommend
manag elect surgic procedur recommend hospit
surgeon minim postpon cancel elect schedul oper endoscopi
invas procedur
march surgeon gener jerom adam advis hospit
cancel elect surgeri referenc american colleg surgeon guidelin
note elect procedur bring possibl coronaviru facil pull
person protect equip store hospit inventori tax personnel
may need respons
two event set cascad effect action state citi municip
announc execut order prohibit strongli recommend postpon elect
impact defer elect hospit
 depart human servic hh offic inspector gener
conduct telephon interview survey hospit administr hospit
across state district columbia puerto rico march
interview focus three key question
difficult challeng respond
strategi hospit use address mitig challeng
could govern best support hospit respond
survey find read entireti via link purpos discuss
highlight find relat
hospit describ increas cost decreas revenu threat
financi viabil hospit report ceas elect procedur servic
decreas revenu time cost increas prepar
potenti surg patient mani hospit report cash reserv
quickli deplet could disrupt on-going hospit oper
one administr explain cash hand becom urgent issu
specialti clinic volum primari care volum
cancel elect surgeri
hospit report lay staff due financi difficulti
exacerb workforc shortag hospit abil care patient
routin patient popul
type hospit especi small rural hospit request financi
assist includ faster increas medicar payment loan grant
one administr state absolut financi nightmar
new york presbyterian hospit voluntari disclosur
march new york presbyterian hospit made voluntari disclosur
bondhold relat situat note take step
cancel elect surgeri arrang temporari space accommod expect
inflow patient volum start ramp tab test capac
result action anticip patient volum estim
would neg impact oper million nyph
budget oper incom million thu extent neg impact
realiz oper loss could million nyph also note
financi market perform could also impact return invest
portfolio well result sought increas line credit
mayo clinic announc cut furlough
articl mprnew org minneapoli april link mayo clinic
implement across board pay cut furlough due project billion loss
year articl chief administr offic jeff bolton note decis
elimin elect surgeri outpati visit right decis protect safeti
patient staff preserv person protect equip led signific
reduct revenu note hospit rochest
capac capac mayo surgeri servic articl note
even chang mayo clinic face forecast million short fall
end year compar record-set billion oper incom
hospit system
alon believ
mani system struggl
financi strain
well prepar
treatment
hospit experi respond pandem result nation puls survey march
hh offic inspector gener publish april
three relief bill relat largest thu far care act
congress presid trump sign three law first coronaviru
prepared respons supplement appropri act sign march
second famili first coronaviru respons act march third largest
coronaviru aid relief econom secur care act sign law
march contain number health-rel provis gener
view market like fourth relief bill
hospit care act includ billion new fund healthcar provid
use reimburs provid healthcar relat expens lost revenu
otherwis reimburs directli attribut accord american
hospit associ fund go made roll basi assist rural
hospit covid-rel care cost prepar patient surg includ lost
revenu halt elect servic small busi loan via paycheck
also expand option acceler payment critic care hospit children
cancer hospit along acut care hospit add-on payment
diagnosi relat group drg rate patient address high cost
associ treat patient sever point around increas telehealth
access care act also elimin billion medicar disproportion share
hospit dsh payment cut reduc cut billion
billion implement cut delay decemb
legisl add new cut current end-dat medicaid dsh
crucial updat rural hospit one govern particular
concern financi viabil lastli addit provis assist rural
provid provid care
even care hospit still like struggl financi
feder american hospit fah nation repres
hospit health system unit state march fah wrote letter hh
secretari azar commend govern effort thu far work
hospit also urg agenc move quickli make payment avail
fah note hospit incur signific financi cost area
disrupt elect non-emerg clinic servic expens incur prepar
respond pandem acquir ventil ppe hospit also
incur higher expens relat direct care cost patient sinc
length stay patient typic patient fah note even
addit add-on payment high cost like cover
fah estim non-emerg servic may equat hospit revenu base
hospit could see servic elimin pandem
moreov fah note revenu loss alon signific financi impact
gener off-set oper cost hospit high labor
high fix cost structur mani hospit struggl surviv econom
put strain
hospit believ put
pressur downstream
med-tech compani
form reduc capital-expenditure spend
well increas pressur
control cost
increas effort clinic
standard price
revenu
help maintain adequ
infrastructur futur
pandem like
financi disrupt physician practic
physician also feel financi disrupt survey physician state across
differ sub-specialti march report healthcar physician survey reduc offic visit
procedur across multipl specialti shown figur physician note in-person offic visit
significantli declin though util telehealth increas ask reason behind decreas
physician respons suggest due patient cancel appoint
report ask physician provid us thought may impact his/her practic figur
provid subset respons relat physician respons believ illustr financi strain and/or
notabl structur chang may occur shift telehealth
think patient offic visit recent day impact patient visit
pleas indic percent increase/decreas rel baselin time last year
increas telehealth appoint
april physician organ head american medic associ wrote letter hh secretari
request immedi financi assist physician letter note congress intend provid physician
practic suffer financi loss due design fund public health social servic emerg
fund care act howev care act requir hh interpret elig broadli includ physician
experienc revenu loss non-reimburs expens result letter urg hh provid one
month revenu physician md nurs practition physician assist enrol medicar medicaid
account financi loss non-reimburs expens use averag monthli payment october-decemb
american dental associ health polici institut conduct poll impact dental practic
week march week april poll show increas number dental practic pay
staff week march versu week april poll week end april includ question
around action dentist would consid current restrict would continu restrict continu end
april june major said would focu cost oper cost adjust staff salari borrow money
address shortfal restrict continu august poll show would consid close sell file
bankruptci
barclay take believ physician financi strain quit notabl strain could lead continu physician
practic consolid physician becom part specialti practic group physician employ
hospit view physician shift employ model away past tradit fee-for-
servic model incentiv util medic devic util could moder devic purchas decis also like
continu migrat away physician c-suit turn may continu put pressur price
limit abil introduc increment new product market place
pleas provid thought may impact practic
commentari financi impact
lesser volum patient lay staff
less revenu may lead financi pressur later
start telehealth signific financi effect
concern financi health small medic practic
commentari telehealth
expect see increas telehealth util
believ telemedicin becom long-stand stapl
practic go forward
hope crisi lead telehealth
go lead big paradigm shift rapid
uptak telehealth
need perman reduc staff number
may put us busi depend long take flatten
telehealth increas
major shift telemedicin may actual
curv viru may kill us first
benefici long last effect insur pay
devast effect whole healthcar increas strain medic
resourc stress time
kill busi
kill practic
loss revenu
worri hospit go bankrupt small commun hospit
alreadi thin margin due loss nonemerg procedur
cut volum significantli creat financi hardship
put strain practic
kill revenu
lower patient volum mean less revenu continu pay rent
switch person visit telehealth visit
forc partial transit telehealth
huge shift telemedicin much higher risk
commun spread ill versu past
much bigger role telemedicin
increas telederm
patient come
expect see increas telehealth util
increas telemedicin major patient oncolog
seen without physic visit definit
decreas patient visit remote/telephone/video
build pay salari staff unsur short term financi health
hope perman see increas
thing brutal right
impact hourli worker salari peopl enjoy time
incom significantli overhead
requir deep thought restructur administr practic
loss revenu
forc close offic yesterday due polici citi
cut salari staff doc
decreas incom staff case load
decreas significantli privat practic surgic take big
difficulti overstaf understaf peopl want work
patient volum way
terribl layoff financi ruin
limit busi result low revenu
devast
significantli reduc offic visit test result lower pay
loss money loss staff rapid increas patient
covid die
organ work furlough physician
wont chang hospit much dramat impact outpati
mark chang practic
hard predict neg short term
comment express fear/concern
crazi stop
chang face medicin year come
situat fluid unpredict
need research find solut elimin
concern unknown regard
need improv safeti healthcar provid
slower process caution pre post
great fear travel public state wide
mandat shelter place
concern state wide ban non-emerg
think practic suffer
money surviv problem see
mani peopl believ serious
ill presid
interest re-elect
sure what els occur
impact least next month
shown figur mani state execut order health depart vari timelin end elect
procedur mandat note timelin extend sinc origin mandate/recommend
put place end timelin end state emerg
state execut order and/or health depart mandat recommend elect procedur
estimate popul total us popelect restrict timelinecov facilitiesmand none provid refer provid ident cdc providedhosp hosp/outpat visit end state provid refer end state end state end state emergencyhospit end state end state provid refer stagger counti end none specifiedallmandatenew end state emergencyallmandatenew none specifiedhospit ascsrecommendationnorth end state noticeallmandaterhod none provid refer barclay medic suppli devic
total state plu district columbia execut order health
depart issu mandat strong recommend regard elect procedur
cover popul howev calcul includ
local counti health depart may recommend includ
individu hospit integr deliveri network polici postpon elect
procedur exampl california state largest popul hasnt
implement state wide order note kaiser permanent postpon elect
non-urg surgeri procedur locat kaiser permanent one
america lead health care provid not-for-profit health plan current
member state district columbia includ california
deferr elect issu
unit state alon action recommending/mand
postpon elect procedur govern outsid unit state also
taken action well
provinc canada also ask hospit ramp elect procedur
march deputi premier minist ontario request hospit
ramp elect surgeri non-emerg clinic activ scotia health
author likewis made announc note effect march elect
outpati visit cancel non-urg diagnost imag appoint
reschedul outpati blood collect servic close complet servic
reduc same-day admiss elect surgic procedur postpon
march nation health system nh england issu letter
chief execut nh trust gp practic primari network provid
commun health servic inform non-urg elect oper need
postpon april latest period least three month nh
gave local discret wind elect activ next day
nh note emerg admiss cancer treatment clinic urgent care
continu unaffect nh estim action free
hospit bed across england nh also note medic fit
leav hospit nh note process block-buy capac
independ hospit
march australian protect princip committe recommend
cancel non-urg elect procedur public privat sector
bed space viral transmiss ppe
conserv
believ import note thing elect procedur volum postpon
sever reason free space hospit prepar surg
preserv person protect equip avoid transmiss
believ concern around viral transmiss like remain
time
even though stay-at-hom order appear flatten curv still
mani case concern stay-at-hom order lift
second wave could develop believ still like concern around expos
healthi patient healthcar facil
moreov worth consid physician survey reduc offic visit
associ patient cancel visit believ fear
physician limit emerg basi exist patient see figur
extent patient go see physician refer
specialist schedul procedur impact
backlog thu think could shift extent physician offic
traffic remain low individu remain fear healthcar facil viru
pleas indic whether agre disagre follow statement regard potenti impact
patient proactiv cancelling/postpon
see patient in-person emerg basi
also believ may challeng make-up procedur
believ one assum system make-up lost
procedur quarter time believ much excess capac
system oper room nurs like overwork shift
moreov believ patient may will go back quickli certain
procedur particular qualiti life elect procedur note
investor brief march note observ trend china
healthcar facil reopen observ patient reluct
return procedur fear may becom infect
dont forget econom sensit healthcar
great recess show healthcar demand immun economi even
passag afford act unit state healthcar insur
still larg link employ moreov past two decad individu
move high deduct health plan influenc consumpt
healthcar servic great recess even individu medicar show
econom sensit healthcar spend
extent economi unit state elsewher mani med-tech
compani multi-national corpor period lower econom activ
experi recessionari trend would expect impact consumpt
healthcar likewis impact medic devic suppli trend
type health insur plan
figur illustr distribut health enrol cover worker type convent health
mainten organ one point domin insur plan rise prefer provid network
past decad signific increas high-deduct health plan save option
convent convent indemn plan one prefer provid network cost share
regardless physician hospit
health mainten organ hmo hmo plan usual limit coverag care in-network doctor
gener cover non-emerg out-of-network servic member gener need referr use
specialist hmo often provid integr care focu prevent well
prefer provid organ ppo ppo lower cost share in-network provid servic member use
doctor hospit provid outsid network without referr addit cost
point-of-servic po po plan consid combin hmo ppo plan like ppo po plan
lower cost share in-network provid servic member use out-of-network provid addit cost like
hmo member design in-network primari care provid must get referr see specialist
high-deduct save option hdhp/so hdhp/so hra hsa treat distinct
plan type even plan would otherwis consid ppo hmo po plan indemn plan plan deduct
least singl coverag famili coverag offer hra hsa-qualifi
distribut health enrol cover worker type
kff employ benefit survey kaiser/hret survey employer-sponsor benefit kpmg survey employer-
sponsor health benefit health insur associ america barclay research
percentag cover worker enrol gener annual deduct
singl coverag firm size
deduct
notabl
increas
amount out-of-pocket cost
individu pay
kff employ benefit survey kaiser/hret survey employer-sponsor benefit
among cover worker aggreg gener annual deduct famili
coverag distribut deduct type
among cover worker aggreg gener annual deduct famili
coverag distribut deduct type
firmsal small firmsal larg admissionoutpati surgerysepar annual deductiblecopaymentcoinsuranceboth co-payment coinsurancecharg per daynon barclay medic suppli devic
put everyth context med-tech
updat model reflect view anticip impact
across coverag univers view greatest
impact med-tech sector like reduct elect
believ definit elect non-urg context like
much broader invest commun may expect also believ
like shift elect procedur physician offic visit
declin believ impact backlog procedur also believ patient
may persist fear contract viru physician may hesit expos
patient higher risk categori non-urg case time come
moreov believ concern regard economi also like impact
individu decis make take time spend money deductibles/co-pays/co-
insur procedur thu dont believ resum elect procedur
easi turn light switch assum elect procedur state order gradual lift
state-by-st sometim late may june slow ramp back believ
take time individu feel comfort return back hospit
determin elect headwind thing import consid
elect procedur
type elect procedurei essenti qualiti life type
procedur essenti priorit higher
set procedur princip perform hospit inpati set
requir number overnight stay icu admiss procedur
perform hospit outpati set ambulatori surgeri center perhap
physician offic believ outpati set may
abl restart easier requir icu admiss extens overnight believ
may greater likelihood delay
rehab requir procedur would requir post-procedur transfer skill
nurs facil inpati rehabilit believ procedur requir
may higher bar perform nearer term like
delay
demograph patient addit risk factor patient undergo
procedur risk factor older age heart failur copd
asthma immunocompromis like higher bar
perform nearer futur like delay
orthoped procedur particularli hip knee replac commonli accept
elect procedur also consid qualiti life elect procedur
view procedur one highli like first defer like
one last come back hospit particularli medicar patient
popul given age popul frequent concomit condit consid
high risk factor higher risk contract sport medicin
procedur also elect natur typic done hospit outpati
ambulatori surgeri center may typic younger patient thu
initi postpon procedur may return sooner set
figur highlight procedur consid elect base variou medic societi
pacemak implant stabl sinu node
dysfunct second-degre av block
atrial fibril ablat stabl
placement primari prevent
upgrad cardiac resynchron
therapi crt stabl patient
atrial flutter ablat stabl patient
svt ablat stabl patient
cardiovers stabl
coronari angiographi intervent
coronari angiographi intervent
pvc ablat stabl patient
checks/interrog absent
balloon pulmonari angioplasti
tavr asymptomat patient
patient consid urgent need
cabg surgeri stabl ischem heart
valv repair/replac
asymptomat urgent need
repair asymptomat ascend
without addit risk factor
surgic treatment atrial fibril
carotid angiographi intervent
endovascular open treatment
intervent claudic
claudic
intervent non-heal wound
non-heal wound without
hip knee arthroplasti
revis surgeri absenc new
ercp stone w/no recent cholang
stent place therapi chronic
tcar surgic
revascular asymptomat
creation dialysi access av fistula
repair asymptomat ascend
without addit risk factor
unruptur abdomin aortic
endovascular open treatment
unruptur thorac aortic
benign bone tumor wait
pain retain function
diseas assess ibd
injuri hand wrist elbow
strictur dilat apc gave
ampullectomi varic band
eu biliari dilat possibl
surgeri fibroid sarcoma
surgeri endometriosi pelvic pain
surgeri pelvic floor prolaps
surgeri urinari and/or fecal
hysterosalpingogram elect
american colleg surgeon american colleg cardiolog canadian journal cardiolog barclay research
figur list common elect procedur physician identifi postpon
common elect procedur identifi physician specialti
intervent
routin svr vt ablat
flexibl sigmoidoscopi scope
lung biopsi interstiti lung
transurethr resect
gastrostomi feed tube
bravo reflux test
egd procedur examin
line esophagu stomach
upper part small
deep brain stimul db
sever compani preannounced/withdrawn guidanc
highlight postpon elect procedur primari factor
trend china broader apac western europ anticip soft unit
state manag updat guidanc plan
releas result april manag note buffalo filter airseal
busi still see posit underli momentum
march withdrew full year guidanc illustr quickli
thing evolv note time
princip confin asia europ though recent day pandem expand
europ unit state limit compani abil estim specif
impact busi compani note may experi materi disrupt
financi result first quarter full-year result on-going spread
march boston scientif withdrew guidanc cite
impact elect procedur postpon manag note expect
neg impact due uncertainti scope durat manag unabl
estim impact plan provid inform earn call april
april boston scientif announc preliminari result cost mitig plan
revenu expect flat slightli organ revenu
expect declin compar compani prior forecast growth
includ impact million relat china
manag note sale trend januari februari in-lin
expect procedur volum significantli declin march
march file withdraw financi guidanc
origin issu januari manag note unpreced
measur slow spread viru taken local govern health
care author global includ deferr elect medic procedur social
contact restrict expect continu signific
neg impact oper financi result result unabl
estim overal impact note could materi plan
provid inform confer call current schedul april
typic market close
april zimmer biomet pre-announce sale note expect sale
constant currenc basi report basi
midpoint report would put sale million versu
bloomberg consensu estim million manag also withdrew
guidanc issu februari
figur display compani product geograph mix provid thought compani exposur elect procedur
sale product categori
barclay commentari elect sale mix
sale geographi
lower elect procedur would
impact lab test volum would
would expect elect volum impact
sale across vascular rhythm manag
believ diabet less affect
heart failur lvad may less impact
though could impact slightli
sale product categori
barclay commentari elect sale mix
sale geographi
avanoss main elect procedur exposur
within pain manag busi
includ acut intervent pain
sale product categori
barclay commentari elect sale mix
sale geographi
axon sacral neuromodul system
elect procedur overact bladder
given earli launch procedur
asc-bas axon could tri
select market mitig
sale product categori
barclay commentari elect sale mix
sale geographi
baxter elect surgeri exposur mainli
tie advanc surgeri anesthesia
medic deliveri sale could impact
infus solut use
renal care immun owe
critic need therapi though
patient may seek extent dialysi treatment
medic
due treatment
sacral shift mostlyu given launch us late barclay medic suppli devic
sale product categori
barclay commentari elect sale mix
sale geographi
becton dickinson bd exposur elect
procedur mainli legaci
medic deliveri solut product
use gener hospit procedur
sale product categori
barclay commentari elect sale mix
sale geographi
view except boston
scientif portfolio product could
consid elect across busi
sale product categori
barclay commentari elect sale mix
sale geographi
expos includ product relat
sport arthroscopi product well
surgic power tool use joint
gener surgeri busi also expos
elect procedur note smoke
evacu total sale
note product consid
perform surgeri filter
subsequ pull guidanc
barclay commentari elect sale mix
sale geographi
typic patient age profil
edward lifesci transcathet heart
valv busi may less immun
convent wisdom suggest due
concern exposur thu
procedur despit usual thought
procedur non-electiveplu
think procedur low-risk tavr
discretionari time
critic may use
sale product categori
orthoped aortic mitral tricuspid heart valv barclay medic suppli devic
sale product categori
barclay commentari elect sale mix
sale geographi
view hillrom least expos elect
procedur product sold howev
hospit physician offic gener
extent slowdown
intuit surgic procedur impact
robot demand could likewis impact
instal hillrom
sale product categori
barclay commentari elect sale mix
sale geographi
 js exposur elect procedur tie
medic devic divis particularli
orthoped busi also surgeri
electrophysiolog busi well
within vision surgic busi
would also elect exposur
patient support line counter hemispher pac barclay medic suppli devic
sale product categori
barclay commentari elect sale mix
sale geographi
view except medtron
portfolio product could consid
elect across busi
sale product categori
barclay commentari elect sale mix
sale geographi
believ heavili expos owe
exposur orthopedics/spin
sale well orthoped
insul
cardiac rhythm heart structur peripher gi barclay medic suppli devic
sale product categori
barclay commentari elect sale mix
sale geographi
view teleflex intervent urolog
urolift elect procedur
treatment bph surgic intevent
access busi could also busi could
also see impact could busi
unit would expect oem impact
like lag effect
sale product categori
barclay commentari elect sale mix
sale geographi
view zb mix heavili expos
elect procedur owe exposur
orthopedicsal
sale trauma
franchis within set less elect
except trauma craniomaxillofaci
product qualiti life
product may delay especi
context recess
headwind physician offic visit lab volum
march quest diagnost cover meehan-u lifesci tool
diagnost analyst issu file provid busi updat note
last two week march lab test volum significantli declin excess
inclus test
factor drive signific declin lab test volum quest cite signific
reduct physician offic visit cancel elect procedur custom close
sever curtail oper voluntarili respons govern order
adopt work-from-hom shelter-in-plac polici
sever compani sell product sold physician offic well
physician offic hospit lab relat diagnost test well product gener
sold physician offic regular offic visit
reduct lab test volum likewis consequ product use
collect test pre-analyt product would includ blood
sampl product needl wing set blood collect tube blood cultur
system within univers believ could impact preanalyt
system busi repres sale
lower lab test volum could also reduc amount revenu diagnost
equip maker well extent contract base test volum
throughput desir hospit lab purchas system assay
coverag univers compani exposur includ becton dickinson diagnost
system sale abbott lab diagnost sale said
becton dickinson abbott lab diagnost product
discuss later report could help mitig lost revenu associ
lower offic visit elect procedur relat revenu
previous mention report hospit face signific financi
pressur relat whether relat capit outlay requir prepar
influx patient loss revenu due postpon elect
procedur consequ focu well financi reason medic devic
compani report hospit capit contract project delay
intuit surgic coverag barclay research inform
compani provid inform purpos invest
recommend barclay research
march us cover file comment covid-
warn us surgeon gener american colleg surgeon
recommend could impact sale result impact could materi april
compani releas preliminari result world-wide procedur increas
approxim y/i note compar manag full year guidanc
rang figur illustr procedur growth trend one see
sequenti deceler procedur growth intuit note latter half
march experienc signific declin procedur volum
europ healthcar system divert resourc manag
intuit note ship da vinci surgic system shown figur
typic step though appear sequenti step-
bit quarter intuit manag comment latter half
march also see disrupt system placement health system focus
intuit schedul report result april manag plan discuss
result market trend greater detail
compani capit equip exposur includ hillrom although believ
capit exposur limit integr tabl motion exposur tie intuit
surgic signific exposur bed believ demand
pandem hospit infrastructur build baxter mainli
infus pump franchis also capit equip within portfolio
well within orthoped surgeri well gener surgeri franchis conm
estim sale consid capit also portion
busi consid capit well within surgic busi well
spinal robot zimmer biomet enter capit equip market
meaning launch rosa robot system typic lab equip sold
lease-reag rental model hotel pay manufactur amount per year base
number test run system per year subject minimum likewis becton
dickinson pyxi medic dispens busi also typic rental busi
also consid oper budget expens
figur highlight select med-tech product could use diagnosi manag treat patient
abbott receiv approv id
system minut clia-wav
april fda grant eua
us steril equip support
decontamin respir
hillrom leader icu bed
product also elect procedur net
edward largest share
diagnost ard
product use diagnos lung failur
acut respiratori distress syndrom
full featur ventil
philip sell non-invas ventil
target hospit
ventil compani typic sell relat dispos other includ
mani ventil compani also
minim equip ventil
bipap devic use ventil
oxygen therapi may help
difficulti breath
use ventil featur
infus solut
product also elect procedur net
denot coverag barclay research inform compani provid inform purpos invest
recommend barclay research
compani announc higher demand
ventil manufactur around global indic increas demand
list two compani note higher level demand med-tech
march hillrom announc global demand sever critic product
grown substanti work significantli ramp product goal
doubl capac follow area
respiratori health especi non-invas ventil current approv
 portabl lightweight ideal treat patient mild-to
includ
emerg depart med-surg post-ventil wean support
icu med-surg unit smart bed
patient monitor diagnost includ connex vital sign monitor
well physic assess tool consum includ thermometri probe
cover blood pressur devic cuff
hillrom note seen materi disrupt suppli chain date
work suppli chain partner minim potenti disrupt
us cover
march announc preliminari product revenu million
bloomberg consensu million reflect report growth
quarterli guidanc origin full year guidanc
trend report growth includ contribut
connect care acquisit barclay global healthcar confer manag
comment typic see product revenu boost time flu
could see benefit context manag note continu
see increas demand product direct oem custom first
day second quarter quarter end march note could continu
see increas demand also note potenti neg impact potenti
interrupt manufactur oper supplier manufactur oper
potenti reduct futur demand overbuy product masimo
withdrew guidanc cite uncertainti around host
confer call april
develop produc monitor technolog includ puls oximetri
sensor capnographi region oximetri sedlin brain function monitor
monitor also sell puls oximetri capnographi product thu view
read-thru note sunday march investor
brief see higher sale puls oximetri product along
ventil respiratori devic collect estim product repres
total sale
coverag
barclay research
inform
compani provid
inform purpos
invest
recommend barclay
colleagu meehan life scienc tool diagnost barclay
test tracker color diagnost test trend estim
creat global diagnost test opportun billion rang
billion march announc cdc-base test
reimburs per test non-cdc test reimburs
exposur within univers abbott
within univers abbott greatest exposur
march abbott receiv emerg use author assay
molecular system instrument run test per day
provid result hour abbott run million test month
march abbott receiv eua test id platform
point-of-car system small lightweight boxdescrib compani size
small toaster id isotherm nucleic acid amplif technolog abbott
estim system place unit state includ physician
offic urgent care clinic also ramp product id instrument
deliv system week test result posit return littl
minut neg minut abbott ramp product deliv
test per day equat million month ultim goal
increas capac million test month june higher beyond earli
april walgreen announc open drive id test
center expect other follow
estim abbott charg around test
host product area viral
transport system swab viral prepackag kit swab-bas specimen
collect portfolio high demand also work
complet diagnost portfolio well
biomedom biogx
coverag barclay
research inform
compani
provid inform
purpos
barclay research
march announc collabor biomedom privat
cover announc releas new point-of-car serolog test detect
antibodi blood confirm past current exposur littl
minut biomedom manufactur product separ becton dickinson note
continu work develop antigen test point-of-car bd
system becton comment price given like reimburs
test around test would estim test like around unclear
amount bd receiv
april biogx privat cover announc fda grant
emerg use author biogx molecular test run bd
max system molecular diagnost platform use hundr laboratori
major hospit nearli everi state across us accord bd
bd system process sampl simultan analyz hundr
sampl per day result avail three hour believ assay like price
around though unclear econom bd
product triag monitor
healthcar profession need medic product triag assess attempt diagnos
monitor patient product need includ thermomet blood pressur
cuff stethoscop swab sampl collect tube puls oximet syring
coverag
barclay research
inform
compani provid
inform purpos
invest
recommend barclay
hillrom us front line busi includ line patient monitor
diagnost technolog primari part legaci welch allyn
busi front line includ compani thermometri blood
us cover us two lead
compani make puls oximetri product
becton dickinson us would also basic product could
use sampl collect tube
accord data american hospit associ
bed unit state number bed declin past two decad owe
consolid hospit industri number bed per person also
declin past two decad
accord american hospit associ base data new york state
bed per person new jersey bed per person
maryland bed per person district columbia bed per
person oregon lowest per washington state close
follow per person california per person way
comparison global unit state rank toward lower end spectrum
bed per person accord oecd health statist data itali
bed china bed south kora bed japan bed
note year indic year analysi
believ hillrom rental bed busi estim approxim
million revenu total sale could benefit state municip
individu health system look ramp medic bed stretcher also believ
hillrom acut care frame franchis estim sale global
major us could benefit well primari focu like
icu bed hillrom leader believ hillrom could benefit increment
order extent buildout relat help off-set revenu
contract upgrad believ would ultim come also
lead manufactur bed
hillrom us us largest manufactur acut care
hospit bed howev hillrom particular leader intens
manufactur mainli region player
arjo arjo ss cover
privat cover
us cover
accord studi john hopkin univers us hospit total
full-featur ventil base studi anoth
basic one full-featur could use emerg
accord american associ respiratori partner
cdc strateg nation stockpil provid necessari resourc respiratori
therapist prepar mechan ventil larg popul public health
emerg note three ventil type strateg nation stockpil
impact uni-v eagl zoll parent compani ashai kasei jt
common newest devic stockpil believ
impact treat major patient home
care ventil low flow oxygen inlet
march presid trump fulli execut defens product act regard
presidenti memorandum product ventil
april presid expand compani via memorandum includ
gener electr ge us hillrom us cover philip phia
na vyair medic privat cover addit contract announc
first dpa contract announc gm philip
first contract defens product act invok presid
trump announc today depart human servic hh
ventil rout strateg nation stockpil sn deploy
locat need
gener motor gm cover brian johnson total contract price
million ventil deliv sn end august
first deliveri ventil schedul june averag price per
ventil
philip phia na cover hassan al-wakeel total contract price
million deliveri ventil sn end decemb
includ deliveri ventil end may averag price
per ventil hassan al-wakeel note philip ventil
contract us govern inform
acquir ventil respiratori busi covidien acquisit
base histor covidien sale breakout estim ventil sale roughli
million total sale relat airway product like endotrach tube
around million sale fiscal
medtron manufactur acut care ventil well portabl ventil puritan
bennett line compani flagship hospit ventil line latest gener
ventil line design provid natur breath softwar design
simpl user interfac ventil featur pav softwar design
reduc patient-ventil asynchroni newport portabl ventil
use home care transport hospit
long-term care emerg
prepared medtron note use invas non-invas
ventil newport compact ideal hospit long-term care
march announc increas product date
track doubl capac manufactur suppli ventil
made galway ireland aim reach ventil per week
april provid statu updat ventil note follow
ramp increas product expect end june
current ship ventil per week custom
around world priorit product ramp
manufactur plan vents/week end april
vents/week end may end june total
expect gener total ventil across platform next
emerg use author eua puritan bennett expect
avail us may provid doctor clinician anoth
option patient devic compact lightweight portabl
ventil use clinic set home devic
avail intern sold countri devic averag sell price
puritan bennet remot access limit releas two hospit
new remot manag capabl allow clinician adjust ventil set
outsid icu compani believ capabl could reduc healthcar work
clinician exposur patient plan expand
limit market releas us custom later april featur well receiv
ventil open sourc initi previous announc publicli
share design specif today announc made
meaning progress three open sourc manufactur bayli medic compani
privat cover foxconn technolog group cover
vingroup joint stock compani vic vn cover sinc launch
registr design specif
higher end ventil price assum blend averag price
asp similar contract dpa would impli
increment opportun includ associ respiratori
hillrom award ventil contract dpa hillrom acquir breath
technolog last year breath ventil product wearabl
ventil provid continu intermitt ventil support individu
requir mechan ventil system provid posit pressur ventil
deliv invas via endotrach tube noninvas via mask provid
ventil support via assist control mode ventil use home
institut set
time acquisit sale annual around million hillrom
current process re-launch product believ award dpa
contract bring hillrom favor brand opportun bode well
product could higher sale
build out icu bed possibl hospit cold look purchas addit
infus pump also note becton dickinson establish medic necess
pathway fda would allow custom access alari infus pump
prior clearanc resolv recal matter becton largest pump
manufacturer/instal base unit state
note howev unclear extent infus solut would net
benefit solut also use elect procedur hospit
treat elect patient overal hospit censu patient volum lower
total infus solut volum sold may net posit believ
someth monitor
cover
 braun privat cover primarili supplier iv solut
extracorpor life support ecl extracorpor membran oxygen
patient sever acut respiratori distress syndrom ard high mortal
rate extracorpor life support ecl extracorpor membran oxygen ecmo
devic relat consum provid higher-end extracorpor heart and/or
lung support ecl use improv outcom patient ard
note geting cardiohelp system market intens care patient suffer
ard sepsi condit associ acut respiratori failur
approv use unit state geting express increas
manufactur product
geting getib ss cover
us cover
patient also report acut kidney injuri kidney failur thu renal
replac therapi may use
freseniu medic fre gy cover hassan al-wakeel-eu med-tech servic
nikkiso jt cover
march abbott announc earn call thursday april first
confer call featur robert ford ceo robert funck cfo
take absenc updat press releas came mid-march
indic endors guidanc end
quarter believ quarter guidanc like impact given
abbott exposur china well compani exposur medic devic well
diagnost lab volum reduc expect weigh core lab
busi dont expect compani assay materi benefit
due manufactur scale meaning test volum
april announc earn call date thursday may
mean quarter safe guidanc year ok think mayb
signal perhap ok reason in-lin consensu estim
dont think necessarili infer much full year guidanc
view bd number put take across portfolio bd receiv
emerg use approv made announc regard partnership
serolog test also obtain path fda hospit obtain medic
necess alari pump posit guidanc impli alari pump sale
howev bd elect procedur exposur dont forget fx rate
us dollar strengthen also impact bd bottom line
april edward announc earn call date thursday april
absenc news suggest edward result reason around
compani guidanc rang provid quarter though dont believ
express view outlook remaind year
believ call interest light recent two-year low risk
data present data well elect procedur
postpon low risk trial show edward sapien valv
superior surgeri year howev longer superior follow-up
rather statist trial show non-inferior trend favor tavr due
reduc hospit rate larg first month post procedur
respect elect procedur april acc/scai consensu
statement publish titl triag consider patient refer structur heart
diseas intervent coronaviru diseas pandem link
tavr sever pandem write group propos
symptomat sever aortic stenosi consid reason schedul
outpati sever critic aortic stenosi class iii-iv chf symptom
minim symptomat sever critic reason consid either urgent
tavr close outpati virtual monitor
asymptomat sever critic reason postpon three month
hospit resum oper elect procedur close outpati
monitor continu
find interest inclus asymptomat sever critic given
indic use edward indic patient symptomat heart diseas due
sever nativ calcifi aortic stenosi fail surgic bioprosthet valv
elect procedur
plan non-urg non-emerg surgic procedur seriou
condit condit improv patient qualiti life urgent
emerg procedur one consid life threaten
believ definit elect non-urg context like
much broader invest commun may expect due
govern hospit mandat reduc risk viru transmiss free bed
space conserv person protect equip
issu guidanc assist health system see framework figur
adult elect surgeri procedur recommend creat sameer siddiqui md adapt
hospit low/no covid-
potenti futur
morbid mortal
non-urg spine ortho
hospit low/no covid-
list procedur nh list wait time consid non-
believ exhaust list non-urg procedur illustr
procedur like postpon england
nation health servic procedur wait time
destruct kidney stone
repair hand tendon
repair umbil hernia
surgeri dupuytren
repair abdomin aortic
surgeri hemorrhoid
surgeri lower back
repair inguin hernia
repair femor hernia
repair tendon knee
treatment trigger finger
elect procedur find physician survey
survey total physician across state across number physician specialti physician
practic activ treat patient averag year
gastroenterologist commun
march american colleg gastroenterolog acg issu joint statement
american associ
studi liver diseas american
gastroenterolog associ american societi gastrointestin endoscopi
statement offer number
recommend one urg gi endoscopi clinic practic strongli
non-urg procedur higher prioriti may need perform
includ cancer evalu prosthet remov evalu
signific symptom societi believ classif procedur non-
urgent/postpon non-urgent/perform may use
march american colleg obstetrician gynecologist acog issu
joint statement american associ gynecolog laparoscopist american
societi reproduct medicin american urogynecolog societi societi
famili plan societi gynecolog surgeon societi maternal-fet
medicin societi gynecolog oncolog endors surgeon gener
statement urg halt elect procedur
statement note obstetr gynecolog procedur delay would
neg affect patient health safeti delay includ gynecolog
procedur relat pregnanc delay would result harm patient
health decis made local-region level consid risk
resourc specif area
march american dental associ recommend dentist postpon elect
procedur next three week help mitig spread help
preserv person protect equip april american dental associ
issu interim recommend dentist keep offic close urgent
emerg procedur april earliest
march american colleg surgeon post on-line link updat non-
emerg procedur initi recommend set quit stir updat
guidanc provid clarif includ statement possibl
defin medic urgenc case sole whether case elect surgeri
schedul also give detail determin whether procedur fact
american colleg surgeon recommend
updat guidanc recommend
hospit surgeri center consid patient medic need logist capabl meet
need real time
medic need given procedur establish surgeon direct expertis relev surgic
specialti determin medic risk incur case delay
logist feasibl given procedur determin administr personnel understand
hospit commun limit take consider facil resourc bed staff equip suppli etc
provid commun safeti well-b
conduct determin base merger assess use contemporari knowledg evolv
nation local region condit recogn mark region variat may lead signific differ
risk patient includ aggreg assess real risk proceed real risk delay
includ expect delay week may requir emerg environ
less preval
march american academi ophthalmolog issu guidanc
recommend ophthalmologist ceas provid treatment urgent
emerg care immedi link recommend appli office-bas care
surgic care note urgenc determin physician judgement
must take account individu patient medic social circumst
march american medic associ ama prais announc
elect surgeri non-essenti medic surgic dental procedur
delay outbreak recommend
administr seema verma said realiti clear stake high need
preserv person protect equip front line fight
elect surgeri procedur recommend similar updat guidelin
issu american colleg surgeon march see link discuss
dental procedur use person protect equip highest risk
transmiss due close proxim provid patient
recommend non-essenti dental exam procedur postpon
surgeri tier postpon includ exampl cancer
neurosurgeri highli symptomat patient transplant trauma cardiac symptom
march american academi orthoped surgeon aao announc
support recommend delay elect surgeri advoc ac
us surgeon gener elect surgeri link websit
march ambulatori surgeri center associ asca publish guidanc
recommend procedur postpon without addit risk patient
delay pandem link concur
risk patient includ aggreg assess real risk proceed
risk delay includ expect delay week may
requir emerg environ less preval exampl
case might still need proceed includ acut infect acut trauma would
significantli worsen without surgeri potenti malign uncontrol pain would
otherwis requir hospit admiss condit prognosi would significantli
worsen delay treatment
march societi gastrointestin endoscop surgeon sage issu
recommend regard surgic respons crisi sage recommend
elect surgic endoscop case postpon minim risk
patient healthcar team minim util necessari resourc
bed ventil person protect equip unexpos healthcar
provid patient
procedur deem urgent necessari sage recommend
laparoscop procedur use devic filter releas
aerosol particl strongli consid due possibl viral
contamin laparoscopi sage note establish
virus releas laparoscopi carbon dioxid thu er
side safeti would appropri
non-urg person clinic/offic visit cancel postpon unless
need triag activ symptom manag wound care patient visit
handl remot possibl person absolut necessari
access clinic maintain possibl avoid patient seek care
emerg room
march heart rhythm societi publish guidanc task forc includ
recommend manag electrophysiolog ep procedur recommend
manag ep clinic guidanc encourag hospit practic follow
exist cdc recommend postpon elect ep procedur hr highlight
follow non-exhaust list elect procedur ablat clinic stabl
patient devic upgrad primari prevent implant left atrial appendag
closur devic implant implant loop record
march vascular societi great britain northern ireland provid gener
principl member manag vascular patient
pandem guidanc recommend defer elect arteri surgeri venou
surgeri asymptomat carotid surgeri surgeri claudic
march societi surgic oncolog sso provid recommend
manag care across specialti assum delay
care
recommend cover breast cancer colorect cancer endocrine/head neck cancer
surfac malign sarcoma
march american colleg cardiolog post gener guidanc
defer non-urg cv test procedur pandem tyler
 gluckman md facc
hub guidanc cite cdc
recommend identifi test procedur potenti defer
articl note follow list see figur adapt repres start
point convers topic like chang depend hospit capac
staff avail
test procedur potenti defer adapt
stress test
test procedur potenti deferr
stress test ecg alon imag echocardiographi radionuclid mri suspect stabl ischem heart
diseas outpati inpati
cardiopulmonari exercis test function assess outpati inpati
transesophag echocardiogram stabl patient outpati inpati
nuclear cardiac imag spect pet outpati inpati
vascular imag asymptomat carotid arteri diseas outpati inpati
vascular imag claudic outpati inpati
imag screen purpos coronari calcium score screen ultrasound assess aaa outpati
in-person cardiovascular implant electron devic cie checks/interrog outpati absent new
inpati
cardiovers stabl asymptomat patient outpati inpati
tilt tabl test outpati inpati
pacemak implant stabl sinu node dysfunct second-degre av block without syncop outpati
implant loop record ilr implant absent cryptogen stroke outpati inpati
placement primari prevent stabl low-risk patient outpati
upgrad cardiac resynchron therapi crt stabl patient outpati inpati
atrial fibril ablat stabl patient without refractori heart failur outpati inpati
atrial flutter ablat stabl patient without refractori heart failur outpati inpati
svt ablat stabl patient outpati inpati
pvc ablat stabl patient outpati inpati
left atrial appendag closure/occlus watchman outpati inpati
lead extract unrel infect symptomat lead failur outpati inpati
cardiopulmonari exercis test function assess outpati inpati
surveil right heart catheter cardiac biopsi post cardiac transplant outpati
hemodynam monitor implant cardiomem outpati inpati
coronari angiographi intervent stabl ischem heart diseas outpati inpati
coronari angiographi intervent non-cardiac preoper evalu outpati inpati
chronic total occlus intervent outpati inpati
coronari brachytherapi outpati inpati
balloon pulmonari angioplasti cteph outpati inpati
renal angiographi intervent outpati inpati
pfo/asd closur outpati inpati
transcathet aortic valv replac tavr asymptomat patient outpati inpati
percutan mitral valv repair mitraclip replac valve-in-valv outpati
left atrial appendag closure/occlus watchman outpati inpati
coronari arteri bypass graft cabg surgeri stabl ischem heart diseas outpati inpati
valv repair/replac asymptomat patient outpati inpati
repair asymptomat ascend aortic aneurysm cm among without addit risk factor famili
histori outpati inpati
surgic treatment atrial fibril includ converg procedur outpati
upper extrem angiographi intervent outpati inpati
lower extrem angiographi intervent claudic outpati inpati
lower extrem surgic revascular claudic outpati inpati
lower extrem angiographi intervent non-heal wound without impend limb/tissu loss outpati
inpati
lower extrem surgic revascular non-heal wound without impend limb/tissu loss outpati
inpati
carotid angiographi intervent asymptomat patient outpati inpati
transcarotid arteri revascular tcar surgic revascular asymptomat patient outpati
inpati
renal angiographi intervent outpati inpati
creation dialysi access av fistula outpati
repair asymptomat ascend aortic aneurysm cm among without addit risk factor famili
histori outpati inpati
endovascular open treatment unruptur abdomin aortic aneurysm aaa cm outpati inpati
endovascular open treatment unruptur thorac aortic aneurysm aaa cm outpati inpati
venou ablat outpati inpati
venou stent outpati inpati
cardiac rehabilit phase inpati outpati
tyler gluckman md facc post american colleg cardiolog websit barclay research
march american colleg surgeon publish guidelin variou
specialti facil thought leader major procedur categori help inform
decis make local level procedur categori includ follow
metabol bariatr surgeri
cancer procedur categori outlin ac organ decision-mak three
phase describ acuiti local situat
phase semi-urg set patient hospit resourc
exhaust institut still icu vent capac covid trajectori rapid
phase ii urgent set mani covid patient icu ventil capac limit
suppli limit covid trajectori within hospit rapidli escal phase
phase hospit resourc rout covid patient ventil icu
breast cancer surgeri guidelin develop breast cancer consortium made
repres napbc coc asbr nccn
patient hospit resourc exhaust institut still icu vent capac covid trajectori rapid escal
case need done soon
feasibl recogn statu hospit
like progress next week
case defer
clinic stage neg tumor
tripl neg posit patient discord biopsi like malign
excis malign recurr
excis benign lesions-fibroadenoma nodul etc
discord biopsi like benign
prophylact surgeri cancer noncanc case
delay snb cancer identifi excision biopsi
lesions- posit neg
tumor respond neoadjuv hormon treatment
altern treatment approach
inflammatori local advanc breast cancer
tumor receiv hormon therapi
tripl neg posit tumor undergo neoadjuv therapi prior surgeri
clinic stage neg tumor receiv hormon therapi
inflammatori local advanc breast cancer receiv neoadjuv therapi prior
mani covid patient icu ventil capac limit suppli limit covid trajectori within hospit rapidli escal phase
case need done soon
feasibl recogn statu hospit
like progress next day
case defer
incis drainag breast abscess
evacu hematoma
revis ischem mastectomi flap
revascularization/revis autolog tissu flap
consid neoadjuv therapi elig case
observ safe remain case
hospit resourc rout covid patient ventil icu capac suppli exhaust
case need done soon
feasibl statu hospit like
progress hour
case defer
incis drainag breast abscess
evacu hematoma
revis ischem mastectomi flap
revascularization/revis autolog tissu flap
case
consid neoadjuv therapi elig case
observ safe remain case
pandem breast cancer consortium napbc coc asbr nccn american colleg surgeon barclay research
colorect cancer surgeri ac issu follow guidanc colorect cancer surgeri
patient hospit resourc exhaust institut still icu vent capac covid trajectori rapid escal
case need done
soon feasibl recogn
statu hospit like
evolv next week two
case could defer
approach delay surgeri
consid
rectal cancer neoadjuv chemoradi respons therapi
cancer concern local perfor sepsi
earli stage rectal cancer adjuv therapi appropri
malign polyp either without prior endoscop resect
prophylact indic hereditari condit
neoadjuv chemotherapi month follow surgeri
rectal cancer case clear earli evid downstag neoadjuv chemoradi
addit wait time safe
addit chemotherapi administ
local advanc rectal cancer recurr rectal cancer requir exent surgeri
addit chemotherapi administ
oligometastat diseas effect system therapi avail
mani covid patient icu ventil capac limit suppli limit
case need done
soon feasibl recogn
statu hospit like
progress next day
nearli obstruct colon cancer stent option
nearli obstruct rectal cancer divert
cancer high inpati transfus requir
cancer pend evid local perfor sepsi
case defer colorect procedur typic schedul routin
transfer patient hospit capac
consid neo-adjuv therapi colon rectal cancer
consid local endolumin therapi earli colon rectal cancer safe
hospit resourc rout covid patient ventil icu capac suppli exhaust patient death like
within hour surgeri defer
case need done
soon feasibl statu
hospit like progress
perfor obstruct activ bleed inpati transfus depend cancer
case sepsi
case defer case
transfer patient hospit capac
american colleg surgeon barclay research
thorac cancer surgeri addit follow guidanc ac note guidanc issu societi surgic
oncolog number addit cancer type
patient hospit resourc exhaust institut still icu vent capac covid trajectori rapidli escal
case need
done soon feasibl
recogn statu
hospit like progress
next week
solid predominantli solid lung cancer presum lung cancer clinic node neg
node posit lung cancer induct therapi cancer esophag cancer greater
chest wall tumor high malign potenti manag altern therapi
stent obstruct esophag tumor
stage start treatment mediastinoscopi diagnost vat pleural dissemin
symptomat mediastin tumor diagnosi amen needl biopsi
patient enrol therapeut clinic trial
predominantli ground glass solid nodul cancer
solid nodul lung cancer cm
pulmonari oligometastas unless clinic necessari press therapeut diagnost indic
case
approach
surgeri impact treatment
patient unlik separ mechan ventil like prolong icu need particularli
elig adjuv therapi give neoadjuv therapi chemotherapi lung cancer
stent obstruct cancer treat chemoradi
debulk endobronchi tumor circumst altern therapi option due increas
risk aerosol stridor post obstruct pneumonia respons antibiot
follow patient neoadjuv local failur salvag surgeri
extend chemotherapi addit cycl patient complet plan neoadjuv cours
perfor cancer esophagu septic
tumor associ infect compromis septic debulk post obstruct pneumonia
manag surgic complic hemothorax empyema infect mesh hemodynam stabl patient
mani covid patient icu ventil capac limit suppli limit covid trajectori within hospit rapidli escal
case need done
soon feasibl
recogn statu
hospit like progress
next day
case
transfer patient hospit phase elig adjuv therapi give neoadjuv therapi
reconsid neoadjuv definit chemo-radi follow patient local failur
thorac procedur typic schedul routine/elect add-on
hospit resourc rout covid patient ventil icu capac suppli exhaust
case need
done soon feasibl
statu hospit like
progress hour
perfor cancer esophagu septic patient
manag surgic complic unstabl patient activ bleed amen nonsurg
manag dehisc airway anastomot leak sepsi
case
transfer patient hospit phase elig adjuv therapi give neo-adjuv therapi
reconsid neoadjuv definit chemo-radi follow patient local failur
american colleg surgeon barclay research
regard cardiac surgeri ac highlight societi thorac surgeon st
websit well john hopkin document guid principl elect procedur
minim potenti exposur surgic peri-op staff aerosol
gener procedur unrecogn asymptomat carrier
minim risk person hospit environ potenti exposur
consist key underli principl social distanc
purpos reduc
minim risk exposur surgic patient
minim use critic suppli equip redirect care
acut patient care patient conserv ppe
equip critic reduc rate util suppli help
ensur avail critic use
blood conserv nation blood suppli drop due elimin
blood drive factor minim elect procedur requir blood
help preserv resourc
staf may becom necessari re-deploy staff help cover acut case load
begin see staff becom infect
icu inpati bed capac cancel elect case requir inpati
resourc preserv resourc acut need
present hr pain control defer oper local excis local
anesthesia outpati set extens excis region gener anesthesia
acut pancreat necrosi
use system antibiot indic superfici local incis drainag local
anesthesia larger and/or deepli locat abscess may amen intervent radiolog
approach incis drainag indic
support care resuscit antimicrobi therapi infect present suspect use
recommend step approach drainag debrid endoscop intervent
radiolog techniqu manag laparoscop open option avail refer
sage guidelin safe use laparoscop approach
laparotomi vs laparoscopi indic
iv antibiot transit po antibiot
abscess ir drainag iv antibiot transit po antibiot
phlegmon iv antibiot transit po antibiot
perfor iv antibiot transit po antibiot consid ir drainag associ abscess
defer intervent pain control achiev
percutan cholecystostomi whenev possibl iv antibiot transit po antibiot
percutan cholecystostomi whenev possibl
depend individu patient comorbid
ercp sphincterotomi
abscess ir drainag iv antibiot transit po antibiot
phlegmon iv antibiot transit po antibiot
iv antibiot transit po antibiot
american colleg surgeon barclay research
ac note american academi orthoped surgeon aao support recommend issu
ac us surgeon gener highlight follow tabl univers pennsylvania
acut pain lower
inabl bear weight
extrem bear weight
concern infect
acut pain upper
extrem move joint
inabl activ move joint
concern -disloc joint
concern -fractur bone
acut chang chronic
injuri w/inabl function
hip knee disloc
acut inabl weight bear
acut pain exacerb
concern periprosthet
sarcoma primari
malign chemo
fall inabl move
acut chronic knee pain
acut chronic hip pain
new onset shoulder elbow
shoulder elbow
elbow shoulder disloc
new loss function
acut lacer tendon
chronic shoulder pain
chronic shoulder elbow
disloc joint reduc
lacer week
acut knee pain injuri
acut shoulder pain
acut ankl pain injuri
acut elbow pain injuri
acut hip pain injuri
acut knee hip pain
unabl weight bear
hip knee disloc
prior hip knee replac
acut pain exacerb
concern infect w/prior
scoliosi neuro deficit
sarcoma primari
malign chemo
fall loss function
acut chang
revis surgeri absenc
new progress neuro
benign bone tumor
unchang chronic pain
function shoulder elbow
lacer tendon
chronic cuff diseas
heal lacer
week
non-op fractur
fractur week
week
univers pennsylvania american colleg surgeon barclay research
provid follow tabl guidanc triag vascular procedur
ruptur symptomat taaa aaa
aneurysm associ w/infect prosthet graft infect
pseudoaneurysm repair candid thrombin inject compress rapidli
aortic dissect acut aortic dissect ruptur malperfus
aortic emerg no aef septic/hemorrhag shock sign impend ruptur
infect arteri prosthesi without overt sepsi hemorrhag shock impend
revascular high grade re-stenosi previou intervent
symptomat carotid stenosi tcar
thrombos nonfunct dialysi access
fistula revis ulcer
renal failur need dialysi access
fistula revis malfunction/st
fistulagram malfunct
av fistula graft placement dialysi esrd
fasciotomi compart syndrom
peripher vascular diseas chronic limb threaten ischemia rest pain tissu loss
peripher angiogram endovascular therapi claudic
surgic procedur claudic
lysi arteri venou
symptomat venou to acut occlus mark swell
thorac outlet syndrom arteri thrombosi
traumat injuri hemorrhag and/or ischemia
acut iliofemor dvt phlegmasia
massiv symptomat iliofemor dvt low risk patient
procedur ulcer secondari venou diseas
amput infection/necrosi tma bka aka
lower extrem diseas non-salvag limb amput
deep debrid surgic wound infect necrosi
amput infection/necrosi toe
alif exposur spine team
surgery/embol uncontrol bleed unstabl patient
surgery/embol bleed stabl patient
mediport immedi infus need
port remov complic
postpon
postpon
postpon possibl
postpon possibl
postpon
postpon
postpon
postpon
postpon
postpon
postpon possibl
postpon
postpon
postpon
postpon
postpon
postpon
postpon possibl
postpon possibl
postpon
postpon possibl
postpon
postpon
postpon
postpon possibl
postpon possibl
postpon possibl
postpon possibl
postpon
postpon
postpon possibl
postpon possibl
postpon
postpon
postpon possibl
postpon possibl
postpon possibl
postpon
postpon possibl
postpon possibl
postpon possibl
american colleg surgeon barclay research
april british societi gastroenterolog joint advisori group provid
updat guidanc endoscopi procedur list emergency/essenti procedur
follow
acut upper gi bleed risk stratifi predict requir endotherapi
obstruct upper lower gi lesion requir stenting/therapi
endoscop vacuum therapi perforations/leak
on-going lower gi bleed intervent radiolog possibl unsuccess
also list defer notic follow
diseas assess ibd
low-risk follow-up repeat scope oesophag heal gastric ulcer heal poor
elect therapeut procedur strictur dilat apc gave rfa poem
pneumat dilat ampullectomi varic band recent bleed
eu biliari dilat possibl stone submucos lesion pancreat cyst without
endoscopi part clinic research
ercp stone recent cholang stent place therapi
chronic pancreat metal stent removal/chang ampullectomi follow-up
move valuat
stock calendar
basi calendar
basi due effect
anticip
distort trend
believ look
use refer year
set price target primarili reli forward price-to-earnings methodolog
believ stock maintain premium multipl given top line bottom line
growth prospect revis price pt appli multipl ep
prior pt base pe
price target deriv combin ev/sal ev/ebitda approach
med-tech compani substanti question growth cash flow outlook
histor trade revenu appli multipl sale
estim estim deriv valu per share appli
multipl adjust ebitda estim arriv valu
thu averag arriv pt prior target base likewis
blend basi use sale estim deriv valu
ev/ebitda valuat deriv per share arriv blend basi
valu axn ev/sal basi price target appli multipl
sale estim million compar smid cap high growth
med-tech compani prior multipl base ev/sal multipl
sale estim million believ lower multipl appropri given risk
pt appli target pe ep estim appli premium
valuat give credit compani balanc sheet strength prior pt also
base pe use ep estim
set price target primarili reli forward price-to-earnings methodolog
price target appli multipl calendar ep prior pt
base pe multipl use ep estim feel comfort use
sampl multipl outer year given greater clariti around alari pump medic
necess pathway well bd product help diagnos treat manag
valu share use price-to-earnings methodolog price target appli
target pe ep prior pt base target pe
ep believ lower target warrant give uncertainti oper
environ
price target methodolog base enterpris valu sale appli ev/sal
multipl sale estim billion arriv price target
smid cap med-tech name similar growth outlook current trade prior
target appli ev/sal multipl revenu estim
set price target primarili reli forward price-to-earnings methodolog
believ multipl ew share like compress given potenti slower growth
believ harder increment penetr tavr market tmtt
opportun like take longer play price target appli price-to-earnings multipl
ep estim prior target appli pe multipl
ep estim believ recent data low risk trial rais
question longer term rel superior tavr rel surgeri
set price target primarili reli forward price-to-earnings methodolog
price target appli price-to-earnings multipl calendar ep
prior target base pe ep estim believ sustain
least market multipl given product mix
price target reflect pe ep use ntm ep estim past
year share trade premium market past year
trade premium market last year trade market
multipl prior target incorpor sum-of-the-part valuat well
reflect histor valuat approach also impli blend pe ep
set price target primarili reli forward price-to-earnings methodolog
price target appli target pe calendar ep estim
growth profil improv expect pe expand closer peer
prior pt assum target pe ep slight discount
high growth med-tech compani trade level
set price target primarili reli forward price-to-earnings methodolog
price target appli pe multipl ep estim expect
multipl compress owe elect procedur capital-expenditure exposur underli
sale growth slow prior price target appli pe multipl ep
assum belief superior growth dynam note great
recess stryker pe fell ntm project earn
set price target primarili reli forward price-to-earnings methodolog
price target appli pe multipl ep estim premium
market other med-tech sector believ warrant given
higher growth potenti former price target assum pe ep
believ overal med-tech multipl make compress given
set price target primarili reli forward price-to-earnings methodolog
appli multipl adjust cash ep estim sinc
zmh/zbh share trade averag pe multipl high low
equat discount appli market multipl time ep
estim arriv price target former price target appli target pe nearli
adjust ep believ lower multipl appropri given current
state hospit environ uncertainti around unemploy henc
uninsur rate uncertainti around hospit capital-expenditure spend trend
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight view share high-
qualiti growth asset believ compani
favor mix busi product
geograph perspect see medic devic
busi particularli diabet key driver
growth go forward believ growth profil
upsid case depend sever key factor
strong growth libr alin approv
adopt new product particularli within medic
devic abil drive margin expans
downsid case driven slower libre/alin
sale fx slowdown emerg market inabl
around likelihood healthcar reform
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight believ balanc
risk/reward even current time
rate stock equal weight expect
elect procedur postpon
weigh pain managm busi
believ recent appoint new ceo could
prove posit catalyst cost
upsid case could driven greater sale
growth greater margin expans cost
save success lead improv
outlook greater recoveri on-q busi
downsid could driven deceler sale
growth trend inabl achiev cost save
unsuccess pressur on-q
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight differenti product
believ axn penetr million sacral
neuromodul market r-snm system
axon readi hit ground run
experienc sale organ physician feedback
posit devic given financi opportun
stock valuat rate compani
upsid driver includ faster adopt r-snm
greater market share gain sacral
would acceler overal market growth
rate introduct new technolog
downsid could stem slower uptak
inabl manufactur suffici quantiti
interstim micro altern treatment oab
expect reset lower
believ appropri level near-
term ep growth significantli aid financi
engin share repurchas believ
warrant lower valuat multipl rel other
sector think risk/reward fairli
upsid case could driven gener
competit less expect greater
success bring new product market
greater-than-expect improv profit
accret
downsid case could driven greater-
pressur renal med deliveri fx rate
inabl drive pharma sale pharma price
inabl expand margin
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
co
mainli due valuat believ alari
pump issu could remain overhang stock
also concern slight capit
exposur well
upsid case ep could driven
synergi associ bard acquisit
improv overal growth rate btk
indic earlier resolut alari pump
downsid case ep could driven
foreign exchang stronger usd could
slowdown emerg market growth/china fda
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight one
highest sustain sale growth profil larg cap
med-tech compani number new
product across busi segment
provid above-averag growth expect
double-digit ep growth continu believ
premium valuat warrant given expect
growth
upsid case could driven new product
regulatori approv time greater traction new
product improv profit success
integr leverag acquisit
downsid case could driven delay
inabl receiv regulatori approv slower
uptak new product greater competit
pressur key area stent structur
heart greater-than-expect price pressur
overweight success
execut turnaround posit deliv
least mid-single-digit sale double-digit ep
growth ex-covid impact view acquisit
buffalo filter posit enhanc
continu success drive high singl digit sale
growth greater succ sale realign
product contribut greater expect
slowdown organ growth comp becom
difficult slowdown hospit capit
equip market invest spend drive
strengthen us dollar competit
larger player
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
underweight believ transcathet
may peak edward face addit
competit believ transcathet mitral valv
tmvr/r opportun year away believ
ew sale growth like slow overal
expect stock pe compress
upsid case ep may driven
better-than-expect tavr sale greater leverag
 stronger uptak tmvr faster-than-
expect time tmvr/r product us
downsid case ep may
driven delay inabl commerci tmvr/r
technolog slowdown tavr sale due
greater expens support tmvr/r product failur
recal fear safeti concern
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ manag
right strategi chang portfolio mix creat
durabl mid singl digit sale doubl digit ep
growth profil compani also believ
compani could benefit pandem
due product mix given plu rel
valuat rate stock overweight
improv sale growth rate driven new product
challeng hospit capital-expenditure environ
capit order delay due inabl
drive acceler top-lin growth increas
competit pressur dilut downsid
overweight believ share like
trade fundament next
month trade closer peers/market
believ fundament solid pharma growth
strong driven darzalex imbruvica
stelara tremfya portfolio move posit
medtech/consum allow least
market growth
upsid driver includ capit deploy drive
faster growth greater success new drug
outcom greater margin expans
downsid risk includ drug price
pharmaceut pipelin lower expect
clinic commerci success medic devic
action drug/devic recal margin eros
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight believ
number new product across busi
allow sustain mid-single-digit growth
expect leverag provid
least high-single-digit ep growth believ
stock valuat still attract despit recent
appreci share ep
upsid case ep success
deploy market share gain key area
cardiovascular structur heart surgic
neurostimul greater margin expans
expect
pressur inabl receiv product approv
market share loss key categori dilut
compani fundament believ share-pric
perform like restrain
outstand acquisit wright medic
on-going integr pend robot
competit knee zimmer biomet see
increment risk elect
procedur hospit capital-expenditure henc uw
organ growth greater success new product
approv success strategy/integr
greater success drive oper margin
orthoped hospit capital-expenditure increas
competit percept thereof knee
particularli robot fx rate inabl drive margin
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
continu grow modestli deceler
success past deal notabl
neotract urolift vsi help acceler
growth achiev warrant premium pe
stock current reflect equal
greater urolift vsi sale greater
improv profit improv
core busi sale growth rate accret
slowdown urolift sale rel
expect challeng within core busi
higher interest rate dilut
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
equal weight view appoint
bryan hanson ceo posit catalyst chang
believ orchestr turnaround
howev believ transform need
like take multipl year see prospect
signific sale margin expans
limit near-term
upsid case could driven improv
market trend orthoped greater success
improv price trend strateg
downsid case could driven inabl
receiv and/or execut new product approv
deterior price addit fda regulatori
exchang stronger us dollar dilut
valuat methodolog risk
valuat methodolog set price target primarili reli forward price-to-earnings methodolog believ stock
maintain premium multipl given top line bottom line growth prospect pt appli multipl ep
risk may imped achiev barclay research valuat price abbott signific exposur
emerg market intern broadli thu chang fx rate could pressur sale ep result new product central
posit view approv adopt new product therefor anoth risk risk includ healthcar reform effort medicar
reimburs chang product recal fda warn letter govern regulatori action libr signific driver
growth chang trajectori key risk factor
valuat methodolog price target deriv combin ev/sal ev/ebitda approach med-tech compani
substanti question growth cash flow outlook histor trade revenu appli multipl
sale estim estim deriv valu per share appli multipl adjust ebitda
estim arriv valu thu averag arriv pt
risk may imped achiev barclay research valuat price risk includ approv
abil compani sustain least mid-single-digit growth time uptak new product abil realiz cost save
target off-set strand cost chang effect tax rate foreign exchang cost optim save on-q risk coolief
competit reimburs product failur restructur save success deploy capit dilut acquisit
valuat methodolog valu axn ev/sal basi price target appli multipl sale estim
million compar smid cap high growth med-tech compani
risk may imped achiev barclay research valuat price risk includ time adopt
clinician abil penetr market competit product approv time line launch particularli interstim micro
fda manufactur issu recal also risk factor reimburs chang
valuat methodolog pt appli target pe ep estim appli premium valuat give credit
risk may imped achiev barclay research valuat price new product import baxter
growth outlook therefor approv uptak new product key risk factor gener competit particularli cyclo
brevibloc could pressur earn and/or extent pressur less expect favor impact fx rate stronger us dollar
could also pressur baxter sale earn outlook risk includ signific reimburs chang fda govern
action also view abil baxter obtain tech-add-on dialyz risk factor believ market current price
co
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli
multipl calendar ep
risk may imped achiev barclay research valuat price upsid risk factor extent becton
success integr bard see greater expect revenue/cost synergi shorter time period resolv alari pump
issu greater success new product downsid fx stronger us dollar commod cost could greater headwind risk
factor includ time success new product delay resolv alari pump issu increas competit key product
drug-coat balloon infus pump signific chang reimburs fda govern action
valuat methodolog valu share use price-to-earnings methodolog price target appli target pe
ep
risk may imped achiev barclay research valuat price key risk upsid downsid
relat trajectori sale growth new product integr upsid risk includ greater success new product
competit product failur anoth key risk factor relat pace elect procedur recoveri downsid risk includ fda regul
product failur and/or recal advers reimburs chang healthcar reform litig outcom inabl drive margin expans
inabl integr acquisit govern action
valuat methodolog price target methodolog base enterpris valu sale appli multipl sale estim
billion arriv price target smid cap med-tech name similar growth outlook current trade
risk may imped achiev barclay research valuat price risk includ abil integr
transact particularli buffalo filter new product approv competit price pressur fda action abil expand oper
margin abil reduc debt
valuat methodolog set price target primarili reli forward price-to-earnings methodolog believ multipl ew
valuat methodolog risk
share like compress given potenti slower growth believ harder increment penetr tavr market
tmtt opportun like take longer play price target appli price-to-earnings multipl ep estim
risk may imped achiev barclay research valuat price greater transcathet aortic valv
replac tavr sale success transcathet mitral tricuspid therapi tmtt could result higher earn expand price-to-earnings
risk factor includ new product approv particularli mitral valv competit product launch signific chang
reimburs product failur valv thrombosi advers long-term outcom may chang usag trend product patent
litig outcom fda govern action
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli
price-to-earnings multipl calendar year ep
risk may imped achiev barclay research valuat price upsid new product drive acceler
sale ep growth accret acquisit continu favor hospit capital-expenditure environ downsid less favor trend
hospit capital-expenditure delay due slower uptak new product strengthen us dollar higher tax rate risk includ
signific reimburs chang fda product approv time competit pressur fda govern action
valuat methodolog price target reflect pe ep use ntm ep estim past year share
trade premium market past year trade premium market last year trade
risk may imped achiev barclay research valuat price downsid risk greater pressur
healthcar reform dilut deal integr issu upsid risk includ new product success success capit deploy favor
litig outcom competit product failur rotat defens stock
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli target
pe calendar ep estim growth profil improv expect pe expand closer peer
risk may imped achiev barclay research valuat price downsid risk includ fx rate
strengthen us dollar could pressur earn stock perform new product key futur success compani
thu extent compani unabl receiv fda approv could advers impact futur outlook product includ
compani surgic robot platform minim futur iter continu blood glucos monitor devic transcathet
valv system upsid greater success new product margin expans risk includ signific reimburs chang
competit pressur product failur fda govern action
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli pe
multipl ep estim expect multipl compress owe elect procedur capital-expenditure exposur
risk may imped achiev barclay research valuat price fx rate recent acquisit could
pressur earn growth competit pressur particularli area knee competitor launch compet robotic-assist
system could impact growth outlook sentiment toward stock time ultim receipt new product approv could
affect outlook risk includ integr wright acquisit signific chang reimburs potenti dilut
associ acquisit product failur fda govern action deterior cash flow could also risk factor
valuat methodolog set price target primarili reli forward price-to-earnings methodolog price target appli pe
multipl ep estim premium market other med-tech sector believ
warrant given higher growth potenti
risk may imped achiev barclay research valuat price upsid extent neotract urolift sale
higher expect could drive upsid sale earn lead higher pe downsid urolift sale disappoint core
growth fail improv fx stronger us dollar deceler non-urolift growth risk includ time receipt new product
approv competit pressur particularli key product like urolift signific chang reimburs fda govern
valuat methodolog set price target primarili reli forward price-to-earnings methodolog appli multipl
adjust cash ep estim sinc zmh/zbh share trade average pe multipl high low
equat discount appli market multipl time ep estim arriv price target
risk may imped achiev barclay research valuat price upsid resolut fda matter
acceler top line growth improv margin profil downsid delay new product approv failur see signific
increas new product uptak neg earn revis addit cost associ on-going manufactur issu risk factor
includ signific reimburs chang competit pressur dilut associ potenti acquisit integr acquir
valuat methodolog risk
busi proce sale busi fda govern action
kristen stewart cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
